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1
GEstAtionAl troPhoblAstiC DisEAsE
Gestational trophoblastic disease (GTD) represents a heterogeneous group of preg-
nancy-related disorders, consisting of the premalignant hydatidiform mole and the 
malignant disorders invasive mole, choriocarcinoma, placental site trophoblastic tu-
mor (PSTT) and epithelioid trophoblastic tumor (ETT) 1,2. The term gestational tropho-
blastic neoplasia (GTN) has been applied collectively to the malignant counterparts 
3. More recently, two tumor-like trophoblastic lesions have been described: exagger-
ated placental site reaction and placental site nodule 4,5. These lesions are generally 
incidental findings in uterine curettages, biopsies or occasionally in hysterectomy 
specimens 6,7. Following these lesions, local recurrence or progression to gestational 
trophoblastic neoplasia is exceptional, therefore no specific treatment or follow-up 
is usually necessary 8.The relevance of the exaggerated placental site reaction and 
placental site nodule consists of possible misdiagnosis of PSTT and ETT. Placental site 
nodules have been described as the benign counterparts of ETT, whereas exaggerated 
placental site lesions show comparison with PSTT 4,9.
Suction curettage is the preferred method of evacuation in patients with suspected 
hydatidiform mole, irrespective of uterine size 10,11. In developed countries, due to 
the introduction of routine ultrasonography in the early 1990s, patients with hy-
datidiform moles are typically diagnosed in the first trimester of pregnancy, when 
symptoms are usually absent 12. Hydatidiform moles can be divided into complete 
and partial hydatidiform mole. Complete hydatidiform moles (CHM) are diploid and 
androgenetic, resulting from duplication of the haploid genome of a single sperm or 
dispermic fertilization of an ovum (Figure 1). In either case, maternal chromosomes 
are lost and nuclear DNA is entirely paternal 2,4. Complete hydatidiform moles are 
characterized by uniform enlarged villi, diffuse hyperplasia and varying degrees of 
atypia in the absence of an ascertainable fetus 6,7. In contrast, partial hydatidiform 
moles (PHM) usually have a triploid karyotype and arise from dispermic fertilization 
of a haploid ovum. Fetal parts may be present and villous changes are more patchy 
and scattered 4,13,14. In some cases, distinction between PHM, CHM and non-molar 
hydropic abortions can be challenging 13,15,16. The subdivision between complete and 
partial hydatidiform moles is of interest, since the malignant potential of both entities 
differs. Post-molar GTN occurs in approximately 15-20% of complete hydatidiform 
moles and 0.5-1% of partial hydatidiform moles and implies further treatment 1,10,17-19. 
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In post-molar GTN, trophoblastic activity persists after evacuation of a hydatidiform 
mole, expressed by a plateau or rise in serum human chorionic gonadotropin (hCG) 
concentration 1,2. The international Federation of Obstetrics and Gynecology (FIGO) 
defines post-molar GTN as: 1) a plateau in hCG concentration in 4 consecutive blood 
samples over a period of 3 weeks, 2) or a rise in hCG concentration for 3 consecutive 
samples over a period of 2 weeks 20-22. An elevated but falling hCG 6 months after 
evacuation is no longer considered an absolute criterion as serum hCG normalization 
will generally occur in these patients 21,23. 
inCiDEnCE
Epidemiological studies have reported wide regional variations in the incidence of 
GTD 24. Our group has previously reported a GTD incidence rate in the Netherlands of 
1.56 per 1000 deliveries per year, with an incidence for hydatidiform moles of 1.34 
a
b
c
Figure 1. Cytogenetic origin of complete hydatidiform mole (CHM) and partial hydatidiform mole 
(PHM). CHM develops after monospermic (a) or dispermic (b) fertilization of an ovum. Maternal 
chromosomes are lost before or just after conception, resulting in a diploid karyotype. PHM re-
sults from dispermic fertilization of a normal ovum (c). This generally results in a triploid karyo-
typea.
a Adapted from Seckl MJ et al. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines 
for diagnosis, treatment and follow-up; Annals of Oncology 24 (supplement 6): Vi 39-vi 50, 2013; 
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per 1000 deliveries per year 25. The incidence rates were derived from population-
based data between 1995 and 2008. The incidence rate of HM was broadly compa-
rable with recent findings of population-based studies in Europe and North-America 
26-28.  Reported frequencies from Asian countries are highly heterogeneous with rates 
ranging from 1 to 3 per 1000 pregnancies in Japan, China and Korea to over 10 per 
1000 pregnancies in Indonesia and India 26,27,29-32. Lack of centralized databases, het-
erogeneity in case definition and inability to adequately describe the population at 
risk (e.g. the number of pregnancies, deliveries or life births in the population) have 
likely contributed to the wide variations in incidence rates worldwide 2,33-35. 
In addition, although morphologically CHM and PHM have distinct histopathological 
features, the subjective nature of the morphological abnormalities give rise to inter-
observer variation in diagnosis 36,37. Especially in the present ultrasound era, when 
evacuation is usually performed at an early stage of pregnancy and classic morpho-
logical features will be less apparent 38,39. The introduction of immune-staining with 
p57kip2, an imprinted marker expressed only by the maternal genome and therefore 
absent in CHM but present in PHM and ploidy analysis such as flow cytometry can 
be helpful in the distinction between PHM, CHM and non-molar hydropic abortions 
13,15,16,39-41. Before the introduction of these ancillary techniques, some complete hyda-
tidiform moles could have incorrectly been classified as PHM or non-molar abortions, 
explaining the wide variation and changes in reported ratios between complete and 
partial hydatidiform moles 15,32,40. 
huMAn ChorioniC GonADotroPin
The glycoprotein hCG is a sensitive marker for monitoring trophoblastic activity in 
pregnancy and gestational trophoblastic disease (GTD) 2,42. To enable early detection of 
those patients requiring further treatment, all patients with hydatidiform mole should 
be subjected to continued hCG surveillance 17. hCG is a heterogeneous molecule, pro-
duced by trophoblastic tissue during pregnancy 42. Beside intact hCG, consisting of an 
α- and β-subunit, other forms of hCG are present in serum such as hyperglycosylated 
hCG, nicked hCG, free β-subunit, free α-subunit, nicked free β-subunit, and β-core 
fragments 43. The production of subunits is under stringent physiological control in 
normal pregnancy and likely differs in pathological events such as a hydatidiform mole 
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43. It is therefore essential to use an hCG assay that detects different forms of hCG 44. 
Although sandwich-type assays can be directed against a variety of epitopes on the 
hCG molecule, the wide range of epitope combinations on the hCG molecule may 
result in different specificity for hCG and its subunits with different hCG assays in use 
45,46. 
In the Netherlands, an in-house developed radioimmunoassay (RIA), based on poly-
clonal antibodies raised in rabbits is used for all measurements in sera sent to the 
Dutch Central Registry for Hydatidiform Moles since 1977 47. The assay is designed to 
detect all native hCG with emphasis on free β-subunit. A highly purified hCG β-subunit 
preparation labeled with Iodine-125 is used as a tracer. The assay is calibrated with 
the third International Standard (IS) for Chorionic Gonadotrophin (WHO, 75-537). The 
cutoff value for normal hCG levels is established at 2 ng/mL, representing the cutoff 
serum concentration at 95% specificity as found in postmenopausal women 48.  
hCG rEGrEssion
Several authors have described serum hCG regression curves, based on patients with 
uneventful serum hCG regression after evacuation of a hydatidiform mole 47,49,50. 
These regression curves  can be used as a reference while monitoring patients af-
ter molar evacuation. Some authors found that an hCG regression curve, based on 
patients with uneventful hCG regression allowed earlier detection of patients devel-
oping post-molar GTN than the FIGO 2000 guidelines 47,49. In the Netherlands, the 
application of such a normogram has resulted in an additional criterion for post-molar 
GTN. The Dutch criteria for post-molar GTN include: 1) a plateau in serum hCG for 4 
consecutive measurements over a period of 3 weeks, 2) or a rise in serum hCG for 3 
consecutive measurements over a period of 2 weeks, 3) and at least one of the values 
should exceed the 95th percentile of an hCG normogram of uneventful hCG decline 
as constructed by Yedema et al. 47. The reason for this additional criterion was the 
observation that 15% of patients with an initial plateau or rise of serum hCG, demon-
strated a spontaneous normalization 47. The normogram as presented by Yedema in 
1993, has been widely used as a reference for both complete and partial hydatidiform 
moles and allows close monitoring of patients, while facilitating identification of those 
developing GTN 47. The normogram was however solely based on uneventful regres-
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sion after complete hydatidiform moles and similar hCG regression in patients with 
partial hydatidiform moles was only presumed. Considering the distinctive features in 
terms of genetics, histology and clinical presentation between complete and partial 
hydatidiform moles, this presumption can be questioned. Moreover, the normogram 
was based on patients with uneventful hCG regression between 1977 and 1989, when 
hydatidiform moles typically presented in the second trimester with classic clinical 
signs of vaginal bleeding, uterine enlargement and hyperemesis 47,51-53. Since the early 
1990s, ultrasonography was widely introduced as part of routine first-trimester clini-
cal management. Consequently, hydatidiform mole patients are generally diagnosed 
at an earlier gestational age, before classical symptoms have developed. As a result, 
lower hCG levels at time of evacuation and earlier hCG normalization are expected 
today and a shift in hCG regression may be anticipated 52,54,55. 
PrEDiCtion oF Gtn 
A number of studies focused on the challenging prospect of predicting post-molar 
GTN. A tool that enables individualized and timely prediction of post-molar GTN 
could be used to either reassure patients at low-risk of post-molar GTN or to identify 
patients at high-risk of post-molar GTN. 
Patients at high-risk of post-molar GTN may benefit from early start of curative 
chemotherapeutic treatment 56,57. Some authors explored the predictive value of 
different biomarkers, including inhibin, progesterone, interleukin-β and CA-125 for 
post-molar GTN 58-63. Although these biomarkers are used for diagnosis and follow-up 
of other gynecologic malignancies, none of these markers can reliably predict which 
patients will undergo a malignant change to post-molar GTN. Most research on pre-
dicting post-molar GTN has focused on serum hCG and different hCG-subunits 43,64,65. 
Van Trommel et al. has shown that hCGα, hCGβ and hCG+hCGβ concentrations are 
significantly elevated in patients who will develop post-molar GTN when compared to 
patients with spontaneous regression after molar evacuation. Others have discussed 
the potential to predict post-molar GTN with the use of other markers such as hyper-
glycosylated hCG or the calculation of hCG ratios 43,65-69. Although these studies under-
line the relevance of serum hCG in post-molar GTN, none of these findings resulted 
in a sufficiently accurate prediction tool to be used in daily practice and diagnosis of 
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post-molar GTN is still based on the criteria as defined by the International Federation 
of Obstetrics and Gynecology (FIGO) 70.
GEstAtionAl troPhoblAstiC nEoPlAsiA
Although gestational trophoblastic neoplasia generally occurs after evacuation of a 
hydatidiform mole, GTN may follow after any kind of gestation including abortion and 
normal pregnancy 71. It is usually unknown whether GTN represents choriocarcinoma 
or invasive mole, since histological confirmation is not essential for classification and 
subsequent choice of therapy 1,72. Biopsy of lesions suggestive of GTN is best avoided 
since massive bleeding may occur 1. When diagnosis of GTN is established, usually 
through hCG follow-up, a metastatic workup with an evaluation for the presence of 
risk factors should be performed 22,73. Chest X-ray is essential, as pulmonary metas-
tases are most common 17. If lesions are visible on chest X-ray, MRI of the brain and 
CT thorax/abdomen are indicated to evaluate the presence of widespread disease, 
which would significantly alter treatment and prognosis 1,21. PSTT and ETT should be 
suspected in case of poor response to chemotherapeutic treatment, especially when 
the disease has developed after a non-molar gestation and hCG concentrations are 
low 21,74. 
sEConD CurEttAGE
In some studies, a second uterine curettage has been recommended for patients with 
GTN 75, most clinicians are however reluctant to recommend routine curettage for 
patients with post-molar GTN 76,77. Generally, the procedure is only used to remove 
residual intra-uterine disease or to control persistent vaginal hemorrhage 77,78. The 
possible benefit of a second curettage has been investigated in several retrospective 
studies. Reported cure rates were inconsistent, with success rates ranging from 9% to 
60% and major complications such as uterine perforation or hemorrhage occurring 
as often as 8% 75-77. Recently, Osborne et al. 78 conducted a prospective multicenter 
trial to better define the efficacy and safety of a second curettage for non-metastatic 
post-molar GTN. They reported cure rates in 40% of patients with non-metastatic 
GTN, whereas major complications occurred in 5% of cases 78. Although these results 
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seem promising, reported success rates may depend on the selection of patients, 
GTN definition and technique used for second uterine curettage. Further research, 
exploring baseline patient characteristics and histology is needed to further evaluate 
the added value of a second curettage in this patient group.
ClAssiFiCAtion oF Gtn
When diagnosis of GTN is made and metastatic workup is performed, patients are 
classified to low-risk or high-risk disease with the use of a prognostic scoring system79. 
Patients with PSTT and ETT should be classified separately as clinical presentation 
and management differs 80-83. Historically, several important predictors of unfavorable 
prognosis such as serum hCG levels, age, antecedent pregnancy and site of metasta-
ses have been proposed for patients with GTN 84,85. In 1976, Bagshawe 84 suggested 
a weighted prognostic scoring system, considering various prognostic factors. It 
provided the basis for several other classification systems, used to predict the poten-
tial for resistance to first-line chemotherapy 70,84,86. The use of these various clinical 
classification systems has proven to be effective, but with a variety of classification 
systems worldwide, meaningful comparison of clinical results was still compromised 
70,84,87,88. Therefore, with the effort of a number of international societies including 
the International Society for the Study of Trophoblastic Diseases (ISSTD) and the 
International Gynecologic Cancer Society (IGCS) the FIGO 2000 classification system 
(Table 1) was developed combining both anatomic and clinical factors 70,79,87. Patients 
with a score of 0-6 are considered low-risk, while patients with a score of 7 or higher 
are considered high-risk 70,79,87. The worldwide introduction of the FIGO 2000 has pro-
vided an opportunity to reach agreement on classification and subsequent treatment 
for patients with GTN. The system is however quite elaborate with an extensive set 
of risk factors, where many relate to tumor bulk and are likely interrelated 85,89-91. In 
the Netherlands, a classification system as proposed by the Dutch Working Party on 
trophoblastic disease is still in use (Table 2) 86,92. The Dutch system is still employed 
today due to the use of a small set of easily retrievable factors and the assumption 
that serious prognostic factors such as liver involvement and antecedent pregnancy 
are taken as absolute criteria for high-risk treatment 92. The use of a separate risk clas-
sification system however excludes the Netherlands from international comparison of 
research results. 
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MAnAGEMEnt oF Gtn
About 90-95% of patients who develop GTN are at low-risk of developing resistance to 
single-agent chemotherapy 93. These patients are usually treated with methotrexate 
combined with folinic acid and actinomycin D as an acceptable alternative in case of 
toxicity or resistance 3,21,74. Patients failing first-line therapy, usually because of resis-
tance, can be salvaged with second and occasionally third-line chemotherapy, result-
ing in an overall survival approaching 100% 94,95. Patients with high-risk classification 
are very unlikely to be cured with single-agent chemotherapy and should therefore 
be treated with a multi-agent chemotherapy regimen 1,83. Overall reported five-year 
survival for high-risk patients varies between 75% and 90% 96-99. Fatal outcome is 
predominantly seen in patients with widespread metastatic disease, especially when 
table 1. FIGO 2000 Classification system for GTN
score 0 1 2 4
Age (years) <40 ≥40 - -
Antecedent pregnancy Mole Abortion Term -
Interval from index pregnancy 
(months)
<4 4-6 7-12 ≥13
Pre-treatment serum hCG (IU/L) <103 <104 <105 ≥105
Largest tumor size (cm) <3 3-4 ≥5 -
Site of metastases Lung Spleen, kidney Gastro-intestinal Liver, brain
Number of metastases - 1-4 5-8 >8
Previous failed chemotherapy - - Single drug Multi drug
A total score of 0-6 = low-risk; score ≥ 7 = high-risk
table 2. Dutch classification system for GTNa
risk group Criteria
low-risk 1. Antecedent pregnancy was a mole or miscarriage
2. Metastases  confined to vagina or lungs 
3. No previous failed chemotherapy 
4. Interval from end of index pregnancy to treatment does not exceed 12 months 
high-risk 1. Antecedent pregnancy was a term pregnancy
2. Metastases in more than one site (outside the uterus) 
3.  Metastases in one or more of the following organs: brain, liver, spleen, kidney, 
gastrointestinal tract 
4. Failure of previous chemotherapy 
5. Interval from end of index pregnancy to treatment exceeds 12 months 
a When one of the high-risk criteria is present, patients will be classified as high-risk and treated 
accordingly
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liver and/or brain are involved 100-102. Today, the most widely accepted treatment for 
high-risk GTN involves the EMA/CO regimen, consisting of etoposide, methotrexate 
combined with folinic acid and actinomycin D alternating weekly with cyclophospha-
mide and vincristine 96-99,103-105. 
As a result of the improvements in chemotherapeutic treatment, a less important 
role remains for surgical procedures. Hysterectomy remains the recommended treat-
ment for PSTT as these tumors appear fairly chemo-resistant with a propensity for 
lymphatic spread 17,80-82. In perimenopausal patients with GTN, primary hysterectomy 
can be considered if fertility preservation is not desired 106,107, whereas secondary 
hysterectomy and metastasectomy  (ie pulmonary resection, craniotomy, liver lobe 
resection) may be essential in chemo-resistant disease 1,102,106,108 or vital hemorrhage 
83,107. Although several authors have assessed the role of surgical procedures in GTN, 
studies were generally small-sized and the possible benefit of these procedures in 
daily practice is still unclear 106-109.  
outlinE oF thE thEsis
This thesis focuses on the detection and classification of GTN, in order to optimize 
management of patients with this rare but potentially life-threatening condition. 
In chapter 2 the trends in incidence of gestational trophoblastic disease in the 
Netherlands are determined with the use of population-based data. For monitoring 
trophoblastic activity in both patients with GTD and normal pregnancy, the glyco-
protein hormone human chorionic gonatotropin, produced by trophoblastic tissue, 
is a sensitive marker. So far, Dutch clinicians relied on a normogram as presented by 
Yedema in 1993, to allow close monitoring of all patients with GTD. The normogram 
was however solely based on uneventful regression after complete hydatidiform 
moles and similar behavior of hCG regression in partial hydatidiform moles was only 
presumed. In addition, due to earlier diagnosis with the introduction of first trimester 
ultrasonography, lower hCG levels at time of evacuation and earlier hCG normalization 
are expected. Chapter 3 describes a new serum hCG normogram for both uneventful 
complete and partial hydatidiform moles, facilitating follow-up and diagnosis of those 
patients developing post-molar GTN. Chapter 4 presents a simple and reliable pre-
diction tool to estimate the individualized risk of post-molar GTN, based on a single 
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serum hCG measurement taken after evacuation. This tool can be used by clinicians to 
either reassure patients at low-risk of post-molar GTN or to identify high-risk patients. 
Early start of chemotherapeutic treatment may be considered for patients at high-risk 
of post-molar GTN, especially when compliance to follow-up is poor. In general, the 
treatment of choice in both low-risk and high-risk patients with GTN involves che-
motherapy. In selected cases, a hysterectomy may be an effective means to either 
reduce or eliminate tumor bulk. In chapter 5 the possible benefits of hysterectomy 
on treatment duration and treatment toxicity are explored for patients with GTN. 
Once the decision has been made that chemotherapy is needed, use of a prognostic 
classification system is an effective means to stratify patients with GTN to single or 
multi-agent chemotherapy. To validate and improve management of GTN worldwide, 
it is essential to reach consensus on the used classification system and subsequent 
treatment protocols. Chapter 6 presents a comparison between the Dutch classifica-
tion system and the internationally used FIGO 2000 for patients with GTN. Use of the 
FIGO 2000 in the Netherlands would enhance comparison with international research 
results. The system is however quite elaborate with an extensive set of risk factors, 
where many relate to tumor bulk and interrelation may be presumed. In chapter 7, 
we re-evaluate all prognostic factors involved in the FIGO 2000 classification system 
and examine whether simplification of this system is feasible. 
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AbstrACt
background: Gestational trophoblastic disease (GTD) represents a heterogeneous 
group of disorders. Wide variations in incidence rates are reported worldwide, 
probably explained by a lack of centralized databases and heterogeneity in case 
definition. Aim of the present study was to determine the trends in incidence of 
GTD in the last 20 years with the use of population-based data. 
Patients and methods: Data on patients with pathologically confirmed diagnosis of 
GTD between 1994 and 2013 were obtained from PALGA, a nationwide archive 
containing all pathology reports in the Netherlands. 
results: In the 20-year period 6341 cases were registered with GTD, representing an 
overall incidence rate of 1.66 per 1000 deliveries per year. An initial rise in inci-
dence rate was seen over the first 10 years (0.075 per year, 95% CI 0.040-0.109), 
followed by a stabilization from 2004 to 2013 (increase per year 0.011, 95% CI 
-0.017-0.040). Although partial hydatidiform mole (HM) was more common in 
earlier years, complete and partial HM reached comparable incidence rates of 0.68 
and 0.64 per 1000 deliveries respectively from 2009 onwards. In the last decade, 
unspecified HM diagnosis declined significantly from 0.14 per 1000 deliveries in 
2003 to 0.03 per 1000 deliveries (per year -0.011, CI -0.016---0.06), suggesting 
improved diagnostic analyses. 
Conclusion: After an initial rise in GTD incidence in the Netherlands, rates remained 
steady from 2004 onwards. As pathological confirmation is currently the norm and 
advanced pathological techniques are now widely available, true steady incidence 
rates may have been reached.
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introDuCtion
Gestational trophoblastic disease (GTD) represents a heterogeneous group of disor-
ders with abnormal proliferation of placental trophoblastic tissue. It encompasses 
complete and partial hydatidiform mole, invasive mole, choriocarcinoma, placental 
site trophoblastic tumor, epithelioid trophoblastic tumor, exaggerated placental-site 
reaction and placental-site nodule. 
Our group has previously reported a GTD incidence rate of 1.56  per 1000 deliveries 
in the Netherlands in the period of 1995 to 2008, with an incidence of HM of 1.34 
per 1000 deliveries per year. The overall  incidence of GTD was low but showed a 
significant increase during the aforementioned time span 1. The incidence rate of 
HM was broadly comparable with recent findings of population-based studies in 
Sweden (1.2 per 1000 deliveries), Turkey (1.22 per 1000 deliveries) and the United 
States (1.19 per 1000 pregnancies) 2-4.  Reported frequencies from Asian countries 
are highly heterogeneous with rates ranging from 1 to 3 per 1000 pregnancies in 
Japan, China and Korea to over 10 per 1000 pregnancies in Indonesia and India 2,3,5-8. 
Lack of a centralized databases, inability to adequately describe the population at risk 
and heterogeneity in case definition have probably contributed to the wide variations 
in incidence rates worldwide. Furthermore, incidence rates may be based on total 
number of pregnancies, deliveries or live births 9-12.
Although of great clinical relevance, comparing incidence rates with respect to cho-
riocarcinoma and PSTT is even more difficult as these conditions are very rare and 
pathological confirmation is not always available 8,9,13.
In the Netherlands a national pathology database named PALGA (Pathologisch Anato-
misch Landelijk Geautomatiseerd Archief) with nationwide coverage since 1991 holds 
all records of histopathologic and cytopathologic diagnoses to facilitate research 
and quality control. This unique nationwide network provides a complete insight in 
incidence rates in the Netherlands 14.  
The present study evaluates trends in incidence for GTD in the Netherlands between 
1994 and 2013 using the population-based pathology database PALGA. 
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Material and methods
Database
The PALGA database is a nationwide archive containing all pathology reports in the 
Netherlands. Present study identified all cases of GTD recorded in the PALGA database 
between 1994 and 2013. 
Patient selection
A selection of the database was performed for patients diagnosed with GTD on the 
following search criteria: complete mole (CHM), partial mole (PHM), mole, invasive 
mole, choriocarcinoma, metastasis choriocarcinoma, intratubular choriocarcinoma, 
persistent trophoblastic disease (PTD), trophoblastic proliferation, placental site 
trophoblastic tumor (PSTT), trophoblastic pseudotumor and epithelioid trophoblastic 
tumor (ETT), placental site nodule and exaggerated placental site reaction, identifying 
7530 records.  Reports were subsequently reviewed and categorized according to the 
WHO classification of GTD: complete and partial hydatidiform mole, invasive mole, 
choriocarcinoma, placental site trophoblastic tumor, epithelioid trophoblastic tumor, 
exaggerated placental-site reaction and placental-site nodule. Multiple abstracts per 
patient involving revisions of one specimen were combined, multiple gestational 
trophoblastic events per patient were however maintained.
Two categories were added: patients with clear diagnoses of HM not otherwise speci-
fied and patients where molar pregnancy could not be distinguished from abortion. 
Inconclusive reports were analyzed and classified by an experienced pathologist, 
specialized in gynecology. Revisions from abroad (N=8) and patients eventually not 
classified as GTD (N=326) were excluded from further analysis. A total of 6341 cases 
were included in the present study. 
statistical analyses
Incidence rates were calculated per  1000 deliveries for HM, GTD, exaggerated placen-
tal site reaction and placental site nodule and per 100,000 deliveries for choriocarci-
noma and PSTT annually. Data on the number of deliveries nationwide were obtained 
from Statistics Netherlands (CBS) 15. All analyses were carried out using Microsoft 
Office Excel 2007 and SPSS for Windows (version 20). 
31Trends in incidence for gestational trophoblastic disease
2
rEsults
Gestational trophoblastic disease
In the 20-year period between 1994 and 2013, a total of 6341 cases were registered 
with gestational trophoblastic disease in the Netherlands, representing an overall 
incidence rate of 1.66 per 1000 deliveries per year. Their median age was 31 years 
(minimum 13, maximum 79). To evaluate potential trends in the annual incidence 
rates, Figure 1 shows the annual incidence rates in the Netherlands between 1994 
and 2013. An initial significant increase is seen over the first 8 years (0.075 per 1000 
deliveries per year, 95% CI 0.040-0.109), followed by a stabilized incidence rate from 
2002 to 2013 (increase per 1000 deliveries per year 0.011, 95% CI -0.017-0.040). 
An overview of the average frequency and incidence of individual entities of GTD is 
shown in Table 1 with moles comprising the majority of cases.
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benign trophoblastic lesions 
Since 1994 a total of 578 cases with a benign trophoblastic lesion originating from the 
intermediate trophoblast were recorded in the Netherlands, involving 306 (52.9%) 
patients with placental site nodule (PSN) and 272 (47.1%) patients with exaggerated 
placental site (EPS). As shown in Figure 2, a significant rise in incidence for placental 
site nodules is apparent from 2004 onwards (increase per 1000 deliveries per year 
table 1. Average frequency and incidence of individual entities of GTD, 1994-2013
GtD diagnosis number Percentage incidencea
Complete Hydatidiform Mole 1993 31.4 0.52
Partial Hydatidiform Mole 2548 40.2 0.67
Invasive Mole 18 0.3 0.01
Unspecified Mole 594 9.4 0.16
Abortion or Mole 449 7.1 0.12
Choriocarcinoma 121 1.9 0.03
Placental Site Trophoblastic Tumor 36 0.6 0.01
Epitheloid Trophoblastic Tumor 4 0.1 0.00
Exaggerated Placental Site Reaction 272 4.3 0.07
Placental Site Nodule 306 4.8 0.08
Total 6341 100 1.66
a Incidence per 1000 deliveries
 
Figure 2. Incidence rates per 1000 deliveries for benign trophoblastic lesions in the Netherlands 
between 1994 and 2013. 
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Figure 2. Incidence rates per 1000 deliveries for benign trophoblastic lesions in the Netherlands 
between 1994 and 2013.
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0.012, CI 0.03-0.20), whereas the incidence rise in exaggerated placental site lesions 
showed a small increase over the years (increase per 1000 deliveries per year 0.003, CI 
0.002-0.004). Median age was 33 (minimum 19, maximum 79) and 32 years (minimum 
16, maximum 58) for placental site nodule and exaggerated placental site respectively, 
with 89.0% of patients under 40 years of age. To evaluate whether knowledge of these 
conditions may be associated with changes in incidence, the number of Pubmed hits 
for each entity per year was calculated. A very modest number of hits varying from 
0 to 7 hits per year however was seen over the years without an apparent increase. 
hydatidiform mole 
In Figure 3 the trends in annual incidence rates for HM over the years are shown. 
Between 1994 and 2013 a total of 5153 cases with HM were registered in the Neth-
erlands resulting in a total incidence of 1.36 moles (complete, partial, unspecified) 
per 1000 deliveries per year. This comprises 81.0% of all GTD. Comparable with the 
incidence pattern in total GTD, a significant increase in molar pregnancies per 1000 
deliveries per year was apparent between 1994 and 2001 (increase per year 0.068, CI 
0.051 – 0.085) followed by an unchanged level since 2002 (increase per year 0.002 , 
CI -0.023 – 0.027). 
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Figure 3. Incidence rates per 1000 deliveries for HM pregnancies in the Netherlands over time 
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CHM and PHM represented 31.4% (incidence 0.52 per 1000 deliveries) and 40.2% 
(incidence 0.67 per 1000 deliveries) of all GTD  cases, respectively. A gradual increase 
in CHM was seen in recent years with incidence rates increasing from 0.46 per 1000 
deliveries in 2005 to 0.74 per 1000 deliveries in 2013 (per year 0.036, CI 0.014-0.059). 
PHM showed a significant increase in incidence from 1994 to 2002 (increase per year 
0.058, CI 0.047-0.069), followed by a significant decline from 2003 onwards (per year 
-0.021, CI -0.037--0.05). The incidence rates for both CHM and PHM have become 
more comparable in recent years, resulting in a change of CHM to PHM ratio from 
0.67 to 1.1. in 2000-2008 and 2009-2013 respectively. The mean maternal age for 
CHM and PHM was 31.1 and 30.4 years respectively. The distribution of CHM and 
PHM per age group is shown in Figure 4 with a significant over presentation of CHM 
in the extreme age groups (P<0.001).
unspecified diagnosis
Patients with a clear diagnosis of HM not otherwise specified and patients with uncer-
tainty concerning discrimination between molar pregnancy and abortion comprised 
9.4% and 7.1% of GTD patients. In the last 10 years, the incidence of both these 
‘unspecified moles’ and ‘abortion or mole’ showed a significant decline as is shown in 
Figure 3. For unspecified moles the incidence decreased from 0.14 per 1000 deliveries 
in 2004 to 0.03 per 1000 deliveries in 2013 (per year -0.011, CI -0.016--0.06). For 
 
Figure 4. Distribution of CHM and PHM according to maternal age between 1994 and 2013.  
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Figure 4. Distribution of CHM and PHM according to maternal age between 1994 and 2013.
35Trends in incidence for gestational trophoblastic disease
2
‘abortion or mole’ the incidence rate decreased from 0.13 per 1000 deliveries in 2004 
to 0.08 per 1000 deliveries in 2013 (per year-0.017, CI -0.032--0.02).
Choriocarcinoma and Pstt 
During the 20-year study period 121 cases of choriocarcinoma were reported in the 
database resulting in an incidence rate of 3 per 100,000 deliveries. Furthermore PSTT 
and ETT were reported in 36 and 4 cases, resulting in an incidence of 0.9 per 100,000 
deliveries and 0.1 per 100,000 deliveries respectively. 
DisCussion
The present study provides a nation-wide overview of incidence rates for GTD and 
underlying entities in the Netherlands. Many epidemiologic studies provide incidence 
rates on GTD by using hospital-based data which inadequately describe the popula-
tion at risk. In these studies, incidence rates may therefore appear higher. In addition, 
regional incidence rates of referral treatment centers cannot be merely compared to 
birth rates in the same region as the region for referral in GTD may be derived from a 
larger geographic region, underestimating the population at risk.
The incidence rates were reported as number of gestational events in relation to the 
number of deliveries. Total number of pregnancies would be the most appropriate 
denominator, including live births, still births, abortions and ectopic pregnancies, 
however data on the total number of pregnancies are not available. Therefore, as the 
denominator live births underestimates the population at risk, a small overestimation 
of the incidence rates observed in the present study  is presumed.
The overall incidence rate of HM in the present study was estimated at 1.36 per 1000 
live births. These rates are fairly consistent with numbers published in population-
based studies from Scandinavia, United Kingdom and the United States States 13,16,17. 
It remains unclear whether regional reporting routines, definition criteria, genetic 
factors or advances in pathologic techniques should be considered. 
Our study provides support for an increased relative risk of CHM at both the upper and 
lower extremes of maternal age, whereas PHM is predominantly seen in the middle 
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of the reproductive period. An age-associated incidence of HM has previously been 
described, with a greater extent of risk at older age, whereas the absolute number of 
pregnancies achieved by older women is greatly diminished 18,19. The age-associated 
incidence of CHM and PHM is less clear, although these distinct conditions have 
different histopathological features and clinical implications. It is hypothesized that 
abnormal fertilization at the beginning and end of the female reproductive period is 
involved, although the underlying pathophysiological mechanism predisposing CHM 
instead of PHM still has to be elucidated 18-21.
Furthermore, an interesting change in ratio of CHM to PHM was seen in the present 
study. This resulted in comparable incidence rates for CHM and PHM in recent years. 
In literature a wide range of ratios has been reported ranging from 0.3 to 3.0 8,22. Mor-
phologically both CHM and PHM have distinct histopathological features, the subjec-
tive nature of the morphological abnormalities however give rise to inter-observer 
variation in diagnosis 23,24. In particular when earlier evacuation is performed in the 
present ultrasound era, classic morphological features will be less apparent 25,26. The 
introduction of immune-staining with p57kip2, an imprinted marker expressed only 
by the maternal genome and therefore absent in CHM but present in PHM and the 
aforementioned ploidy analysis can be helpful in the distinction between PHM, CHM 
and non molar hydropic abortions 27-29. Before its introduction CHM could have incor-
rectly been classified as PHM or non-molar abortions, explaining the wide variation 
and changes in ratios 8,22,28. The incidence of both ‘unspecified moles’ and ‘abortion 
or mole’ also showed a decrease over time, further supporting this hypothesis. The 
ploidy analysis should be performed on selected paraffin embedded slides instead of 
the complete sample as maternal decidua will obscure results, containing maternal 
diploid karyotype. Review by a histopathological specialist is therefore recommended.
An accurate incidence rate of choriocarcinoma and PSTT/ETT is less well known. 
Problems arise as variations in diagnostic criteria and study intervals exist. In the pres-
ent study an overall incidence rate of 3 choriocarcinoma per 100.000 deliveries was 
shown (1.9% of all registered GTD cases). PTT and ETT are even rarer, representing 0.6 
% and 0.1 % of all registered cases in the Netherlands. GTD however is primarily diag-
nosed using clinical parameters such as the biochemical marker hCG and radiological 
findings, therefore histological parameters are not always available. The reported 
incidence is therefore likely an underestimation of the true incidence rate.  
37Trends in incidence for gestational trophoblastic disease
2
In contrast to HM and choriocarcinoma, benign lesions of the intermediate trophoblast 
have been recognized only relatively recent. Both PSN and EPS are usually incidental 
findings in uterine curettages, biopsies or occasionally in hysterectomy specimens, 
irregular uterine bleeding has however been reported 30 31. In the present study, both 
entities typically occurred in the reproductive age groups, with only few patients over 
50 years of age. This likely represents persistence of the lesions following an earlier 
pregnancy. Local recurrence or progression to persistent disease has not been docu-
mented, therefore no specific treatment or follow-up is necessary. The relevance of 
their existence is represented by possible misdiagnosis of PSTT and ETT. Placental site 
nodules have been described as the benign counterparts of ETT whereas exaggerated 
placental site lesions show comparison with PSTT 32,33. To the best of our knowledge, 
no previous population-based incidence rates on benign intermediate trophoblastic 
lesions have been reported. The rise in incidence rate for PSN may be explained by 
raised awareness of the lesions, this is however not supported by a coexisting rise in 
hits (publications) on pubmed. In difficult cases, Ki-67 immunostaining can be help-
ful as the benign counterparts are characterized by low proliferation. In cases where 
uncertainty about the diagnosis still persists, follow-up with measurement of human 
chorionic gonadotropin concentration in serum should be recommended 30,33,34. 
The influence of ethnicity, with Asian population in particular, has previously been 
suggested as a possible explanation for differences in GTD incidence 3,6. The afore-
mentioned lack of centralized databases with predominantly hospital-based data 
however likely plays a large role. Furthermore, in the Dutch population, the rise in 
proportion of Asians due to immigration has only shown a rise of 0.9% in 20 years, 
therefore this alone could not clarify the initial rise in incidence as reported. 
Part of the initial increase in GTD incidence found in this study may be explained by 
improvement of the diagnostic analysis. Due to better understanding of this rather 
rare condition among pathologists a better distinction between hydropic products of 
conception and molar pregnancies can be made 32. HM may have been more common 
than was generally appreciated in previous years 22. Furthermore immunostaining 
with P57kip2 and ploidy analyses such as flow cytometry and in situ hybridization 
can be extremely valuable in pathological diagnosis of partial molar pregnancies by 
demonstration of triploidy 22,26-29,35. As pathological confirmation is the norm and di-
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agnostic pathological techniques are now widely available and recommended in cases 
of suspected molar gestation, a true steady incidence rate may have been reached. 
However, with the increasing popularity of medical induction of spontaneous and 
induced abortions rather than surgical treatment, it may still be difficult to obtain 
pathological confirmation for some early conception products 8,36. 
A limitation of this study is the retrospective design and although inconclusive reports 
were reviewed by an experienced pathologist who is specialized in gynecology, no 
pathological review was performed. Also an overview of used diagnostic tests was 
not always available from the pathology abstracts as registration of their use was not 
mandatory. 
Strengths of the study include the size of the material and the population-based data 
over an extended time span. Although many countries monitor and report incidence 
of GTD, not many have been able to report a population-based overview. 
In conclusion, the overall incidence of GTD in the Netherlands has been steady over 
the past decade. Incidence rates for HM and GTD are consistent with rates from pre-
vious population-based studies in Western countries. PHM occurs more frequently 
than was previously assumed. The introduction of p57kip2 and ploidy analysis has likely 
improved the accuracy of the diagnosis and therefore the actual estimates of GTD 
cases as identified from the Dutch pathological database. Further research on the 
actual use and contribution of these techniques to diagnosis and follow-up should be 
implemented, ideally contributing to a standardized and accurate histopathological 
approach for all cases suspect of GTD. 
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AbstrACt
objective: To develop a serum hCG normogram for both uneventful complete and 
partial hydatidiform moles in the first-trimester ultrasound era.
Methods: An hCG normogram for both complete and partial hydatidiform moles was 
constructed, based on 639 patients with uneventful serum hCG regression after 
evacuation between 1990 and 2014. Serum hCG was measured by an in-house 
developed radioimmunoassay (RIA), detecting both intact hCG and free β-subunit. 
It has been in use for all serum measurements sent to the Dutch Central Registry 
for Hydatidiform Moles since 1977. 
results: Since introduction of routine first-trimester ultrasonography lower pre-
evacuation and follow-up serum hCG concentrations were observed. When com-
pared to complete hydatidiform moles, patients with a partial hydatidiform mole 
had significantly lower pre-evacuation serum hCG concentration (median 4400 ng/
mL and 875 ng/mL, respectively, P<0.001) and earlier hCG normalization (median 
seven weeks and six weeks, respectively, P<0.001) but higher gestational age (mean 
11.5 weeks and 13.0 weeks, respectively, P<0.001). For both complete and partial 
hydatidiform moles, 95% of patients reached normal serum hCG concentrations 
within fourteen weeks after evacuation. 
Conclusions: A normogram for the detection of GTN was developed for complete 
and partial hydatidiform moles. Although interesting from a scientific perspective, 
the small divergence in hCG regression between complete and partial hydatidiform 
moles will be of little importance in clinical practice, as actual differences in regres-
sion will encompass just days. To promote clarity and unity in daily practice we 
therefore propose a combined normogram, to be used as a reference guideline for 
follow-up after evacuation of a hydatidiform mole. This normogram will be compli-
ant with patients in today’s clinical practice. 
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introDuCtion
The glycoprotein hormone human chorionic gonadotropin (hCG), produced by tropho-
blastic tissue, is a sensitive marker for monitoring trophoblastic activity in pregnancy 
and gestational trophoblastic disease (GTD). In post-molar gestational trophoblastic 
neoplasia (GTN), trophoblastic activity remains after evacuation of a hydatidiform 
mole, expressed by a plateau or rise in serum hCG concentration 1,2.  
The International Federation of Obstetrics and Gynecology (FIGO) defines post-molar 
GTN as: 1) a plateau of hCG concentration in 4 consecutive blood samples over a 
period of 3 weeks, 2) a rise of hCG concentration for 3 consecutive samples over a 
period of 2 weeks, or 3) persistence of detectable hCG concentration 6 months after 
evacuation 3. An elevated but falling hCG concentration 6 months after evacuation 
is no longer an absolute criterion, because with continuous surveillance, in all these 
patients spontaneous serum hCG normalization eventually occurred 4. 
Follow-up after evacuation of a hydatidiform mole with serial serum hCG measure-
ments is essential, as patients with GTN require further chemotherapeutic treatment 
5-8. Reference by a normogram allows close monitoring of all patients and facilitates 
early identification of those developing GTN 9. Post-molar GTN occurs in approximately 
15-20% of complete hydatidiform moles (CHM) following evacuation and occurs less 
frequently in partial hydatidiform moles (PHM), with approximately 0.5-1% 6.  
In 1993 Yedema et al. 9 constructed a normogram, based on 130 patients with un-
eventful hCG regression following a complete hydatidiform mole between 1977 and 
1989. At that time, hydatidiform moles typically presented in the second trimester 
with classic clinical signs of vaginal bleeding, uterine enlargement and hyperemesis 
10-12. Since the early 1990s however, ultrasonography is widely introduced as part of 
routine first-trimester clinical management. Consequently, hydatidiform mole pa-
tients are generally diagnosed at an earlier gestational age, before classical symptoms 
have developed. As a result, lower hCG levels at time of evacuation and earlier hCG 
normalization are expected today 11,13,14. 
Furthermore, although the normogram as presented by Yedema et al. 9 has been used 
for both complete and partial hydatidiform moles, the normogram was solely based 
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on uneventful regression after complete hydatidiform moles and similar behavior 
of hCG regression in partial hydatidiform moles was only presumed. Complete and 
partial hydatidiform moles however comprise distinct features in terms of genetics, 
histology and clinical presentation 15-17, raising the question whether the presumption 
of similar hCG regression for both complete and partial moles is legitimate.  Complete 
hydatidiform moles are characterized by uniform enlarged villi, diffuse hyperplasia 
and varying degrees of atypia, in absence of fetal tissue 15,18. Genetically a complete 
hydatidiform mole is typically diploid, with all chromosomes from paternal origin 1,19. 
In contrast, most partial hydatidiform moles have a triploid karyotype, fetal parts may 
be present, villi may vary in size and shape and hyperplasia is only focal with mild 
atypia 1,15,19,20. 
Aim of the present study was to develop a serum hCG normogram for both uneventful 
complete and partial hydatidiform moles, applicable as a reference in the first-trimes-
ter ultrasound era. The possible benefit of separate normograms for both complete 
and partial hydatidiform moles in daily clinical practice was evaluated. 
MEthoDs
Patients
The Dutch Central Registry for Hydatidiform moles at the Radboud University Medi-
cal Center Nijmegen (Radboudumc) was established in 1977. This voluntary registry 
serves as an epidemiological database and provides a nationwide centralized hCG 
measurement service for gynaecologists. Between 1977 and 2014, 4586 patients were 
registered. Since routine first-trimester ultrasonography was gradually introduced 
in the early 1990s, likely affecting mean gestational age and pre-evacuation serum 
hCG, for the present study patients were included from 1990 onwards. The following 
exclusion criteria were applied: diagnosis of GTN, hysterectomy or second curettage 
performed following hydatidiform mole, recurrence of disease after normalization, 
new pregnancy during follow-up and patients for whom hCG serum measurement 
performed at the central registry was either limited to less than 2 measurements or 
unavailable. 
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GTN was defined according to the FIGO 2000 guideline. In line with the Dutch guide-
lines, the following criterion was added to this definition: at least one of the values 
should exceed the 95th percentile of an hCG normogram of uneventful hCG decline as 
constructed by Yedema et al. 9.
All hCG measurements were performed using an in-house developed radioimmuno-
assay (RIA), based on polyclonal antibodies raised in rabbits [21]. This assay has been 
utilized centrally for all measurements in sera sent to the Dutch Central Registry for 
Hydatidiform Moles since 1977 and was described and likewise employed for con-
struction of the normogram as presented by Yedema et al. in 1993 9. The assay is 
designed to specifically detect both intact hCG and free β-subunit. A highly purified 
hCG β-subunit preparation labeled with Iodine-125 was used as a tracer. The assay 
was calibrated with the third International Standard for hCG (WHO, 75-537). The 
cutoff value for normal hCG levels was established at 2 ng/mL, representing the cutoff 
serum concentration at 95% specificity as found in postmenopausal women 21.  
statistics 
Serial hCG levels were pooled per ‘week since evacuation’ to obtain sufficient data 
points: i.e., week 0 represents the day of evacuation up to day 6 post-evacuation. 
Results were log-transformed to calculate the 5th, 50th and 95th percentile cutoffs per 
week post evacuation and subsequently plotted into a normogram. hCG normaliza-
tion time was defined as the time in weeks from uterine evacuation of the mole until 
the time of the first normal hCG value. Differences in parametrical data were assessed 
by two-tailed student’s t test. Non-parametric data were compared using two-tailed 
Mann-Whitney U test. Analyses were carried out using Microsoft Office Excel 2007 
and SPSS for Windows (version 22).
rEsults
Between 1990 and 2014, 324 patients diagnosed with complete hydatidiform mole 
and 315 patients with partial hydatidiform mole were eligible for further analyses. A 
total number of 5088 serum hCG measurements were used, with a median of eight 
measurements per patient. Pre-evacuation serum hCG measurements were available 
in 121 cases. Median pre-evacuation serum hCG was 3800 ng/mL (minimum 48 ng/
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mL, maximum 35,000 ng/mL). Median half-life in the first part of hCG regression 
(week 0-3) was 3.0 days (minimum 2.3, maximum 6.4 days). In the second part of hCG 
regression (week 3-6) median half-life was 7.4 days (minimum 3.0, maximum 24.2 
days). Figure 1 represents the serum hCG normogram for all uneventful hydatidiform 
moles. Some typical serum hCG courses of both patients with spontaneous regression 
and post-molar GTN are plotted in Figure 2. As shown, spontaneous regression after 
initial rise, even in combination with hCG levels exceeding the 95th percentile line can 
occasionally occur.
 
 
Figure 1. Fifth, 50th and 95th percentile lines of serum human chorionic gonadotropin (hCG) 
regression after evacuation of  complete and partial hydatidiform moles. The three dashed lines 
correspond to the calculated 5th, 50th and 95th percentile, based on the available dataset of serum 
hCG in all patients with uneventful regression, the continuous lines indicate the smoothed trend 
lines. The serum hCG cutoff concentration of 2 ng/mL is presented by the horizontal dotted line. 
 
Figure 1. Fifth, 50th and 95th percentile lines of serum human chorionic gonadotropin (hCG) re-
gression after evacuation of  complete and partial hydatidiform moles. The three dashed lines 
correspond to the calculated 5th, 50th and 95th percentile, based on the available dataset of serum 
hCG in all patients with uneventful regression, the continuous lines indicate the smoothed trend 
lines. The serum hCG cutoff concentration of 2 ng/mL is presented by the horizontal dotted line.
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Figure 2. Some examples of serum hCG regression after evacuation of a hydatidiform mole. a) 
spontaneous regression after hydatidiform moles, b) serum hCG course in patients with gestational 
trophoblastic neoplasia before start of therapy. The horizontal dotted line represents the serum hCG 
cutoff concentration of 2 ng/mL 
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) Figure 2. Some examples of serum hCG regression after evacuation of a hydatidiform mole. a) 
spontaneous regression after hydatidiform moles, b) serum hCG course in patients with gesta-
tional trophoblastic neoplasia before start of therapy. The horizontal dotted line represents the 
serum hCG cutoff concentration of 2 ng/mL
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Clinical features for both complete and partial hydatidiform moles are listed in Table 1. 
Gestational age at time of evacuation was significantly lower in patients with a com-
plete hydatidiform mole compared to patients with a partial hydatidiform mole (mean 
11.5 weeks and 13.0 weeks respectively, P<0.001). Patients with a complete hyda-
tidiform mole had significantly higher pre-evacuation serum hCG levels than patients 
with a partial hydatidiform mole (median 4400 ng/mL and 875 ng/mL, respectively, 
P<0.001). Furthermore, later normalization of serum hCG was seen in patients with 
complete hydatidiform moles when compared to partial hydatidiform moles (median 
seven weeks and six weeks respectively, P<0.001). hCG half-life in the second phase of 
regression however was significantly shorter in patients with complete hydatidiform 
moles when compared to patients with partial hydatidiform moles (median 6.9 and 
7.9 days respectively, P<0.01). Median serum hCG levels per week after evacuation 
are shown in Table 2. For both complete and partial hydatidiform moles, 95% of the 
patients reached normal serum hCG levels within fourteen weeks since evacuation 
(Table 3), demonstrating overall small divergences.
Figure 3 represents a comparison between the serum hCG normogram of all unevent-
ful complete hydatidiform moles in our study cohort and the historic cohort, as 
presented by Yedema et al. in 1993 9. When considering serum hCG levels per week 
since evacuation, compared to the historic cohort of Yedema et al. regression in our 
study group has shifted substantially to the left. 
table 1. Clinical features of patients with complete and partial hydatidiform moles
Complete 
hydatidiform Mole
Partial 
hydaditidorm Mole P
N Mean (95% CI) N Mean (95% CI)
Maternal Age, years 323 29.8 (29.1-30.5) 315 30.2 (29.7-30.8) 0.349*
Gestational age, weeks 256 11.5 (11.1-11.9) 252 13.0 (12.6-13.5) <0.001*
N Median (min-max) N Median (min-max)
Pre-evacuation hCG (ng/mL) 89 4400 (133-35,000) 32 875 (48-8700) <0.001+
hCG disappearance time (weeks) 284 7 (2-26) 286 6 (0-25) <0.001+
hCG half-life first phase (days)a 69 3.0 (2.3-6.4) 16 3.1 (2.4-4.9) 0.822 +
hCG half-life second phase (days)b 145 6.9 (3.0-22.4) 81 7.9 (3.1-24.2) <0.01 +
* Student’s  t test
+ Mann-Whitney U test
a Week 0-3 since evacuation
b Week 3-6 since evacuation
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table 2. Serum hCG levels per week after uterine evacuation for patients with complete and par-
tial hydatidiform moles
Weeksa Complete hydatidiform Mole Partial hydaditidorm Mole
N Median hCG in ng/mL 
(min-max)
N Median hCG in ng/mL 
(min-max)
P b
Pre-evacuation 89 4400 (133-35,000) 32 875 (48-8700) <0.001
0 82 1181 (5-82,000) 32 242 (6-77,000) 0.013
1 169 105 (5-960) 74 24 (1-1800) <0.001
2 202 33 (1-1300) 127 12 (1-1400) <0.001
3 206 14 (1-1200) 156 5 (1-527) <0.001
4 201 7 (1-8450) 149 3 (1-150) <0.001
5 208 4 (1-770) 154 2 (1-120) <0.001
a Weeks since evacuation
b Mann-Whitney U test 
table 3. Cumulative percent rate of patients with hCG normalization after uterine evacuation
Cumulative percentage 1% 2.5% 5% 50% 95% 97.5% 99%
Complete hydatidiform Mole
Weeks after evacuation 2 2 3 7 14 19 23
Partial hydatidiform Mole
Weeks after evacuation 1 1 2 6 14 17 22
 
Figure 3. Fifth, 50th and 95th percentile lines of serum human chorionic gonadotropin (hCG) 
regression after evacuation of complete hydatidiform moles in cohort Yedema 1993 (9) (dashed lines) 
and present cohort (continuous lines) compared. The horizontal dotted line represents the serum 
hCG cutoff concentration of 2 ng/mL. 
 
 
 
Figure 3. Fifth, 50th and 95th percentile lines of serum human chorionic gonadotropin (hCG) re-
gression after evacuation of complete hydatidiform moles in cohort Yedema 1993 (9) (dashed 
lines) and present cohort (continuous lines) compared. The horizontal dotted line represents the 
serum hCG cutoff concentration of 2 ng/mL.
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DisCussion
A serum hCG normogram for both uneventful complete and partial hydatidiform 
moles was constructed, applicable as a reference in the first-trimester ultrasound era. 
We observed lower hCG regression curves and earlier hCG normalization in the pres-
ent study compared to the normogram formerly presented by our group in 1993 9. 
Earlier diagnosis aided by routine ultrasonography in the first trimester of pregnancy 
has likely resulted in a left-time shift of serum hCG regression in the present study, 
when compared to the normogram presented by Yedema et al. 9. 
Thus far, regression was solely based on uneventful regression after complete hyda-
tidiform moles and similar behavior of serum hCG regression for partial hydatidiform 
moles was merely presumed. The distinct genetic, histological and clinical character-
istics of partial hydatidiform moles, however, requires an evaluation of a separate 
normogram and its clinical value in daily practice. Interestingly,  patients with partial 
hydatidiform moles presented with lower pre-evacuation serum hCG levels and ear-
lier hCG normalization time. This cannot merely be explained by an earlier diagnoses 
and evacuation of hydatidiform mole in these patients, as gestational age in this group 
was in fact higher when compared to patients with complete hydatidiform moles. 
The relative delay in evacuation in patients with partial hydatidiform moles may be 
explained by the typical features of partial hydatidiform moles on ultrasonography. 
Partial hydatidiform moles may present with fetal parts on ultrasonography in contrast 
with complete hydatidiform moles, where fetal parts are usually absent. Confirmation 
of a non vital, pathologic pregnancy may therefore be delayed 19. 
In addition, the presence of different hCG subtypes may influence the hCG concen-
tration measured and explain differences in hCG determination between partial and 
complete hydatidiform moles 22.
hCG is a heterogeneous molecule, produced by trophoblastic tissue during pregnancy 
23. Beside intact hCG, consisting of an α- and β-subunit , other forms of hCG are present 
in serum such as hyperglycosylated hCG, nicked hCG, free β-subunit, free α-subunit, 
nicked free β-subunit, and β-core fragments 22. The production of subunits is under 
stringent physiological control in normal pregnancy and likely differs in pathological 
events such as a hydatidiform mole. Berkowitz et al. suggested an association be-
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tween the percentage of free hCGβ and level of differentiation and hyperplasia of the 
trophoblast 24. Considering the lower degree of hyperplasia in partial hydatidiform 
moles, one could  hypothesize that in the case of partial moles, less free hCGβ is 
produced as compared to complete moles 24,25.  
Although interesting from a scientific perspective, the small divergence in hCG 
regression between both complete and partial hydatidiform moles will be of minor 
importance in routine clinical practice, as actual differences in regression will encom-
pass just days. Considering the normogram as a guideline during follow-up, a possible 
delay for patients with partial hydatidiform moles therefore yields no therapeutic 
consequences. Use of one normogram, as presented in Figure 1, will promote clarity 
and unity in daily practice, even before the type of molar pregnancy is confirmed by 
pathology. We note that the configuration of a normogram will be as dynamic as the 
patient group it affects, and the type of assay used. Changes in future practice may 
therefore require new adjustments over time. 
ConClusion
In line with the internationally accepted criteria for diagnosis and treatment of GTN, 
the course of serum hCG (expressed by a plateau or rise) should be included in the 
decision to start chemotherapeutic treatment 26,27. We constructed a serum hCG nor-
mogram for both uneventful complete and partial hydatidiform moles, updating the 
normogram as presented by Yedema et al. 9, which is applicable as a reference in the 
first-trimester ultrasound era. The normogram can assist follow-up of patients with 
both complete and partial hydatidiform moles after evacuation and support detection 
of post-molar GTN. Especially in patients with poor compliance to follow-up, this may 
be of vital importance. 
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AbstrACt
objective: Development of a clinically suitable prediction tool for patients with com-
plete hydatidiform moles, to enable early prediction of post-molar GTN based on a 
single serum hCG measurement. 
Methods: Serum hCG levels taken between 1 and 4 weeks after evacuation were ret-
rospectively evaluated for patients with uneventful serum hCG regression (n=319) 
and patients with diagnosis of post-molar GTN (n=149), treated between 1990 and 
2014. Logistic regression was used to generate nomograms for every week after 
evacuation, based on serum hCG measurements at that given week. Performance 
was determined by concordance index and calibration curves.
results: All nomograms had good to excellent ability to distinguish between patients 
who will develop post-molar GTN and patients with uneventful hCG regression, 
reflected by a c-index value increasing from 0.83 in week 1, to 0.95 in week 4.  
Discussion: With our nomograms, we developed a simple and reliable tool to estimate 
the individualized risk of developing post-molar GTN, based on a single serum hCG 
measurement taken after evacuation. These nomograms can be used by clinicians 
to either reassure patients at low-risk of post-molar GTN or to identify high-risk 
patients. Early start of chemotherapeutic treatment may be beneficial in patients 
at high-risk of post-molar GTN, especially in case of poor compliance to follow-up.
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introDuCtion
Gestational trophoblastic disease (GTD) comprises a spectrum of pregnancy-related 
disorders including the premalignant complete and partial hydatidiform moles and 
the malignant conditions of choriocarcinoma and placental site trophoblastic tumor 
1,2. The term gestational trophoblastic neoplasia (GTN) has been applied collectively to 
the malignant counterparts 3. The glycoprotein hCG, produced by trophoblastic tissue, 
is a sensitive marker for monitoring trophoblastic activity in gestational trophoblastic 
disease (GTD) 2,4. To enable early detection of those requiring further treatment, all 
patients with GTD should be subjected to hCG surveillance 5.
In post-molar GTN, trophoblastic activity persists after evacuation of a hydatidiform 
mole, expressed by a plateaued or increased serum hCG concentration 6,7. Post-molar 
GTN occurs in approximately 15-20% of complete hydatidiform moles (CHM) and in 
0.5-1% of partial hydatidiform moles (PHM) and implies further treatment 1,5,8-10. 
To date, it is still unclear why some hydatidiform moles develop into post-molar GTN, 
while others show spontaneous regression after evacuation. Although much effort 
has been made to evaluate the predictive value of clinical characteristics, such as 
advanced maternal age, history of molar pregnancy and large ovarian cysts, these 
factors have shown to be only weak predictors of post-molar GTN 2,11,12. Most stud-
ies have therefore focused on the tumor marker hCG. Several investigators have 
mathematically evaluated whether hCG regression patterns of patients who go into 
spontaneous remission after molar evacuation differ from those who develop post-
molar GTN 13-17. Others have discussed the potential to predict post-molar GTN with 
hCG ratios obtained at different intervals 18,19. Although these studies underline the 
relevance of serum hCG in post-molar GTN, none of these findings resulted in a suf-
ficiently accurate prediction tool to be used in daily practice 14,15,17-19. 
Few authors have discussed the possibility to predict post-molar GTN for patients 
with a complete hydatidiform mole, using a single serum hCG measurement after 
evacuation 18,20. In some of these studies, pre-evacuation serum hCG levels and hCG 
levels taken in the first weeks after evacuation appeared predictive of post-molar 
GTN, but never with enough accuracy to guide individual management 12,18,20,21.
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A tool that enables individualized and timely prediction of post-molar GTN could be 
used to either reassure patients at low-risk of post-molar GTN or to identify patients 
at high-risk of post-molar GTN. 
Early initiation of chemotherapeutic treatment might be beneficial in patients at high-
risk of post-molar GTN, especially when compliance to follow-up is poor. Aim of the 
present study was to develop a simple and reliable tool to enable early prediction of 
post-molar GTN based on a single serum hCG measurement.  
MEthoDs
Patients
The Dutch Central Registry for Hydatidiform moles at the Radboud University Medical 
Center was established in 1977. This voluntary registry serves as an epidemiological 
database and provides a nationwide centralized hCG measurement service for gy-
necologists. Between 1977 and 2014, 4586 patients were registered. Routine first-
trimester ultrasonography was gradually introduced in the early 1990s, affecting 
mean gestational age at diagnosis and pre-evacuation serum hCG. In the present 
study, we therefore included patients diagnosed between 1990 and 2014. All patients 
with available serum hCG data, obtained in the first four weeks after evacuation of a 
complete hydatidiform mole and analyzed at our institution were evaluated. The fol-
lowing exclusion criteria were applied: hysterectomy or second curettage performed 
before diagnosis of GTN was made, recurrence of disease after normalization or a new 
pregnancy during follow-up. 
GTN was defined according to the FIGO 2000 guideline (i.e., mola hydatidosa with 
serum hCG plateauing for three consecutive weeks or rising over a period of two 
consecutive weeks). In line with the Dutch guidelines, the following criterion was 
added to this definition: at least one of the values should exceed the 95th percentile 
of an hCG normogram of uneventful hCG decline as constructed by Yedema et al. 
17. Patients were divided into two groups: those with uneventful serum hCG regres-
sion after evacuation of molar pregnancy (non-GTN group) and patients with proven 
diagnosis of GTN (GTN-group).
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All hCG measurements were performed using an in-house developed radioimmuno-
assay (RIA), based on polyclonal antibodies raised in rabbits 22. This assay has been 
utilized centrally for all measurements in sera sent to the Dutch Central Registry for 
Hydatidiform Moles since 1977. The assay has been designed to specifically detect 
both intact hCG and free β-subunit. A highly purified hCG β-subunit preparation 
labeled with Iodine-125 was used as a tracer. The assay is calibrated with the third In-
ternational Standard (IS) for Chorionic Gonadotropin (WHO, 75-537). The cutoff value 
for normal hCG levels was established at 2 ng/mL, representing the cut-off serum 
concentration at 95% specificity as found in postmenopausal women 22.  
Serial hCG levels were log-transformed and pooled per ‘week since evacuation’ to 
obtain sufficient datapoints: i.e., week 0 represents the day of evacuation up to day 
6 post-evacuation. For the GTN-group, the hCG measurements taken after start of 
curative therapy (chemotherapy, hysterectomy or a curative second curettage) were 
excluded from analysis. 
statistics
Logistic regression analysis was carried out to identify the predictive value of a single 
hCG measurement for the development of post-molar GTN. The hCG measurements 
were added as a continuous variable. Nomograms were subsequently generated using 
R version 3.2.4 with the rms packages (http://R-project-org) 23. Weighting was derived 
from this analysis. Performance was assessed by evaluating model fit, discrimination 
and calibration. The discriminative ability of the prognostic models, or the ability to 
distinguish women with low-risk of post-molar GTN from women with high-risk of 
post-molar GTN, was expressed by means of the concordance index (c-index). For a 
binary outcome, c is identical to the area under the receiver-operating characteristics 
(ROC) curve (AUC) 24. C-indices of 0.6-0.7, 0.7-0.8, 0.8-0.9 and 0.9-1 represent fair, 
good, very good and excellent discriminative models, respectively 25. Calibration 
was assessed graphically by means of the R package rms 25. Calibration refers to the 
agreement between the predicted probability for post-molar GTN and the observed 
probability in the dataset. For example, if we predict a 20% risk of post-molar GTN for 
a particular patient, the observed frequency of post-molar GTN for similar patients 
should be approximately 2 out of 10 patients. In a calibration plot, the predicted GTN 
probabilities (x-axis) are plotted against the observed GTN probabilities (y-axis). Ide-
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ally, if predicted and observed probabilities agree over the whole range, the plots 
show a perfect line of equality. 
The internal validity of the models was tested using the bootstrapping method in 
which the selection and estimation process was repeated 500 times. Each of these 
repetitions resulted in the creation of a new dataset (bootstrap sample) by draw-
ing cases with replacement from the original data. A correction for optimism in the 
c-index was derived from the bootstrap method to yield a bias-corrected c-index. In 
addition, a shrinkage factor was estimated to correct for statistical over optimism. A 
correction for optimism is necessary when a regression model becomes more complex 
and may begin to describe the random error or noise instead of the true underlying 
relationship 26. 
Baseline features were compared using two-tailed Mann-Whitney U test for non-
normally distributed data and two-samples Student’s t test for normally distributed 
data. Analyses were carried out using the statistical packages of R (version 3.2.4), 
Microsoft Office Excel 2007 and SPSS for Windows (version 22).
rEsults
baseline characteristics
Between 1990 and 2014, 319 patients diagnosed with uneventful serum hCG regres-
sion following complete hydatidiform mole (non-GTN group) and 149 patients with 
post-molar GTN (GTN-group) were eligible for further analyses. A total of 1310 serum 
hCG measurements were performed between 1 and 4 weeks after evacuation, with 
a median of three measurements per patient. Baseline characteristics of both groups 
are presented in Table 1. Patients with uneventful serum hCG regression had compa-
rable gestational age at time of evacuation as patients with post-molar GTN (mean 
11.6 weeks and 11.3 weeks, respectively) and comparable maternal age (mean 29.3 
years and 30.6 years, respectively). Furthermore, patients with uneventful regression 
had significantly lower pre-evacuation serum hCG levels than patients with post-molar 
GTN (median 5,000 ng/mL and 12,000 ng/mL, respectively, p<0.001).
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nomogram development
Nomograms were generated for week 1-4 to predict the post-molar GTN risk, based 
on the hCG measurement taken in that week (Figure 1). The hCG measurement (ng/
table 1. Baseline features of patients with uneventful serum hCG regression and patients with 
post-molar gestational trophoblastic neoplasia a
non-Gtn group Gtn-group P
N Mean (SD) N Mean (SD)
Maternal Age (years) 319 29.3 (6.9) 149 30.6 (7.0) 0.07b
Gestational age (weeks) 241 11.6 (3.2) 109 11.3 (3.2) 0.50b
N Median (min-max) N Median (min-max)
Pre-evacuation hCG (ng/mL) 92 5,000 (300-35,000) 49 12,000 (4-120,000) <0.001c
hCG week 1 (ng/mL) 192 107 (3-4,600) 94 430 (26-10,000) <0.001c
hCG week 2 235 33 (2-1,300) 109 300 (23-19,000) <0.001c
hCG week 3 234 15 (2-1,200) 112 487 (14-28,000) <0.001c
hCG week 4 231 7 (2-8,450) 103 400 (18-29,000) <0.001c
a Data shown for all patients with baseline features available
b Student’s t test
c Mann-Whitney U test
 
Figure 1. Nomograms for the prediction of post-molar GTN based on a single serum hCG 
measurement (ng/mL). The serum hCG measurement (ng/mL) is presented on a log-scale in the first 
row, which corresponds to the risk predictor of GTN in the row with that given weeknumber. The 
probability of post-molar GTN can be determined by drawing a vertical line connecting hCG at the 
top of the diagram and the risk scale at the bottom of the nomogram. For example, an hCG value of 
100 ng/mL measured in week 3 corresponds to a 50% probability of post-molar GTN. 
Present hCG (ng/mL)
Probability week 1
Probability week 2
Probability week 3
Probability week 4
 
 
 
Figure 1. Nomograms for the prediction of post-molar GTN based on a single serum hCG mea-
surement (ng/mL). The serum hCG measurement (ng/mL) is presented on a log-scale in the first 
row, which corresponds to the risk predictor of GTN in the row with that given weeknumber. The 
probability of post-molar GTN can be determined by drawing a vertical line connecting hCG at the 
top of the diagram and the risk scale at the bottom of the nomogram. For example, an hCG value 
of 100 ng/mL measured in week 3 corresponds to a 50% probability of post-molar GTN. 
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mL) is presented on a log-scale in the first row of Figure 1 and corresponds to the 
risk predictor of GTN in the row with that given week number. The probability of 
post-molar GTN can be determined by drawing a vertical line connecting present hCG 
at the top of the diagram and the risk scale at the bottom of the nomogram. For 
example, when a patient would present with a serum hCG measurement of 100 ng/
mL in week 3, this corresponds with a 50% probability of post-molar GTN. In Table 2, 
an overview of hCG values and corresponding probabilities per week since evacuation 
is given.
Discriminative accuracy and internal validation
In week 1 and 2, the c-index after correction of optimism is classified as very good (c-
index 0.83; 95% CI 0.70-0.93 and c-index 0.90; CI 0.75-0.95, respectively). The c-index 
after correction of optimism for week 3 and 4 is classified as excellent (c-index 0.94; 
95% CI 0.90-0.96 and c-index 0.95; 95% CI 0.92-0.97, respectively). This indicates that 
the models have good to excellent ability to discriminate between subjects who will 
or will not develop post-molar GTN. 
The calibration plots, that provide a graphic representation of the agreement be-
tween prediction and actual outcome in our dataset are shown in Figure 2. For all 
table 2. hCG values per week (ng/mL) with corresponding risk probabilities for post-molar GTNa.
hCG value (ng/ml)
Probability Week 1 Week 2 Week 3 Week 4
0.01 5 3 2 1
0.05 33 16 10 6
0.1 61 30 19 12
0.2 123 53 37 24
0.3 190 79 54 37
0.4 275 109 75 53
0.5 389 147 103 75
0.6 537 199 141 103
0.7 776 269 218 151
0.8 1202 398 286 234
0.9 2406 691 512 426
0.95 4365 1121 870 758
0.99 14000 3236 2570 2398
a The cutoff value for normal hCG levels is established at 2 ng/mL.
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models, there was no significant deviation in the calibration plots, indicating that the 
predicted risk of post-molar GTN was consistent with the actual post-molar GTN risk. 
To evaluate whether risk prediction was steady over time, Figure 3 shows the con-
secutive probabilities for week 1 to 4 as derived from the nomograms, for patients 
either exceeding 80% post-molar GTN risk in the previous week or patients with a 
post-molar GTN risk remaining below 20% in the previous week. The Figures represent 
a selection of patients since serial weekly measurements were not always available. 
In week 1, 19 patients exceeded the 80% post-molar GTN risk, 18 of these patients 
 
Figure 2. Calibration of all nomograms. Predicted GTN probabilities (x-axis) are plotted against the 
observed GTN probabilities (y-axis). Ideally, if predicted and observed probabilities agree over the 
whole range, the plots would show a perfect line of equality (dotted line). The black lines represent 
the apparent relation between the predicted and observed probabilities. The grey area represents 
the 95% confidence interval. C-index and R2 are given for every model in the corresponding Figures.  
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Model fit
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Figure 2. Calibration of all nomograms. Predicted GTN probabilities (x-axis) are plotted against 
the observed GTN probabilities (y-axis). Ideally, if predicted and observed probabilities agree over 
the whole range, the plots would show a perfect line of equality (dotted line). The black lines 
represent the apparent relation between the predicted and observed probabilities. The grey area 
represents the 95% confidence interval. C-index and R2 are given for every model in the corre-
sponding Figures.
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developed post-molar GTN in a later stage. A decline to ≤80% post-molar GTN risk 
in the following weeks was seen in 2 out of the 19 patients initially at high-risk of 
post-molar GTN. For 119 patients, the post-molar GTN risk was below 20% in week 
1. Spontaneous regression was seen in 107 of these patients in a later stage. In nine 
out of the 119 patients at low-risk of post-molar GTN, a rise to ≥20% post-molar GTN 
risk was seen in a later stage. In week 2, 53 patients exceeded the 80% post-molar 
GTN risk, 49 of these patients developed post-molar GTN in a later stage. For one out 
 
Figure 3. Evaluation of the consiste cy in risk prediction over time. Th  consecutive probabilities as 
derived from the nomograms are shown for patients exceeding the 80% post-molar GTN risk (left 
column) and patients with a post-molar GTN risk remaining below 20% (right column). The involved 
number of patients and post-molar GTN rate are shown in the corresponding Figures a.  
 
 
a The Figures represent a selection of patients since serial weekly measurements were not always 
available. 
 
 
 
 
 
Figure 3. Evaluation of the consistency in risk prediction over time. The consecutive probabilities 
as derived from the nomograms are shown for patients exceeding the 80% post-molar GTN risk 
(left column) and patients with a post-molar GTN risk remaining below 20% (right column). The 
involved number of patients and post-molar GTN rate are shown in the corresponding Figures a. 
a The Figures represent a selection of patients since serial weekly measurements were not always 
available.
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of the 53 patients at high-risk of post-molar GTN, a decline in the post-molar GTN 
risk to ≤80% was seen in the following weeks. The post-molar GTN risk was below 
20% for 180 patients in week 2. Spontaneous regression was seen in 165 of these 
patients in a later stage. In four of these patients at low-risk of post-molar GTN, a rise 
to ≥20% post-molar GTN risk was seen. Finally, 74 patients had a post-molar GTN risk 
exceeding 80% in week 3, whereas 68 of these patients indeed developed post-molar 
GTN later on. Two patients at high-risk of post-molar GTN in week 3 showed a decline 
to a ≤80% post-molar GTN risk in week 4. A post-molar GTN risk below 20% in week 
3 was seen in 197 patients. One hundred and eight-six of these patients showed a 
spontaneous regression in a later stage. Only one out of these 197 low-risk patients 
showed a rise to ≥20% post-molar GTN risk in week 4.
DisCussion
In the present study, we developed and internally validated nomograms to estimate 
the individual risk of post-molar GTN based on a single serum hCG measurement. 
Generally, the decline in serum hCG was considered a predominant factor in the 
prediction of post-molar GTN and several regression curves have been developed to 
facilitate early identification of post-molar GTN 15-17,27. In these regression corridors, 
weekly serum hCG measurements are plotted in a regression curve, to establish 
whether a given hCG level is still within the normal range. These tools can be helpful 
as a reference guideline, but will not provide an individualized risk estimate.
Few studies have discussed the possibility to predict post-molar GTN based on serum 
hCG measurements taken in the first few weeks after evacuation 18,20,21. Most of these 
studies primarily focused on pre-evacuation serum hCG and hCG taken in the first 
two weeks after evacuation. In studies presented by Kang et al. 18 and Mousavi et al. 
21, the ratio between current hCG measurement and previous hCG measurement was 
recognized as a better predictive factor for post-molar GTN than serum hCG in week 
1 or 2 alone. Based on ROC-curves, the optimal cut-off point was chosen and serum 
hCG measurements were divided into two categories to predict the risk of post-
molar GTN. A limitation in this approach perhaps lies in the reduction of serum hCG 
measurements to two categories, whereas the association between serum hCG and 
post-molar GTN should probably be considered as a gradual scale. Additionally, only 
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measurements taken in the first two weeks after evacuation were evaluated in these 
analysis. Wolfberg et al. 20 presented a thorough evaluation of the predictive value 
of serum hCG measurements taken between 1 and 8 weeks after evacuation. Their 
analysis provides an important first step in the recognition of serum hCG measure-
ments as a reliable predictor for post-molar GTN, providing clinicians with a rough 
estimate of the post-molar GTN risk. In their study, measurements were categorized 
into five categories to provide risk estimates per week. The risk estimates were there-
fore still coherent with, and limited to the chosen intervals. 
With the use of nomograms as presented in this study, one can estimate the indi-
vidualized risk of post-molar GTN as early as one week after evacuation, based on 
serum hCG alone. The nomograms are a practical and effective tool for prediction of 
post-molar GTN. With a c-index value ranging from 0.83 in week 1, to 0.95 in week 
4, all nomograms had good to excellent ability to distinguish women with low-risk of 
post-molar GTN from women with high-risk of post-molar GTN and appeared steady 
over time. 
In developing countries, early identification of patients with high-risk of post-molar 
GTN can be crucial, as resources are restricted and compliance of patients to follow-
up may be limited 28. Early identification of those at high-risk of post-molar GTN may 
however be equally valuable in developed countries. In this patient group, early start 
of curative therapy could ideally result in a shortened treatment period and earlier 
opportunity of a renewed pregnancy. Administration of chemotherapy to patients at 
high-risk of post-molar GTN, characterized by a risk exceeding 80% can therefore be 
considered under these circumstances when the benefit of empiric chemotherapy 
outweighs the risk of toxicity 29. 
Considering the use of the nomograms presented in this study, a few limitations 
need to be addressed. First of all, despite the rather large sample size, serial weekly 
measurements were not always available, the models for week 1-4 were therefore 
based on a smaller subset of patients. Furthermore, hCG is a heterogeneous molecule 
comprising several subunits such as hyperglycosylated hCG, free β-subunit and free 
α-subunit 30. Most hCG assays detect native hCG and its β-hCG subunits in equimolar 
amounts, whereas our in-house developed radioimmunoassay (RIA) preferably de-
tects β-subunits over the native hCG. As a consequence, in the present form, the 
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models only apply to the specific assay at the Dutch Central Registry of Hydatidiform 
Mole. A validation of the concept presented in the present study is needed, before 
the tool can be used in a wider context. 
ConClusion
We developed and internally validated nomograms to predict the risk of post-molar 
GTN using a single serum hCG measurement. With the use of these nomograms, 
clinicians can provide proper counseling of all complete hydatidiform mole patients 
and identify patients at high-risk of post-molar GTN. Early start of chemotherapeutic 
treatment can be considered in this patient group, especially when compliance to 
follow-up is poor. 
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AbstrACt
background: Despite the undoubted effectiveness of chemotherapeutic treatment in 
gestational trophoblastic neoplasia (GTN), problems related to toxicity of chemo-
therapy and chemo-resistant disease have led to reconsideration of the use of hys-
terectomy. Aim of the present study was to evaluate indications for and outcome 
of hysterectomy in patients with GTN in a nation-wide cohort.
 Methods: Between 1977 and 2012, we identified all patients diagnosed with GTN 
and treated with hysterectomy from the Dutch national databases. Demographics, 
clinical characteristics and follow-up were recorded retrospectively. 
results: One hundred and nine patients (16.5% of all registered patients with GTN) 
underwent hysterectomy as part of their management for GTN. The majority of 
patients was classified as low-risk disease (74.3%), post-molar GTN (73.5%) and 
disease confined to the uterus (65.1%). After hysterectomy, complete remission 
was achieved in 66.2% of patients with localized disease and in 15.8% of patients 
with metastatic disease. For patients with localized disease, treated with primary 
hysterectomy, treatment duration was significantly shorter (mean 3.2 weeks and 
8.0 weeks respectively, p=0.01) with lower number of administered chemotherapy 
cycles (mean 1.5 and 5.8 respectively, p<0.01) than patients in a matched control 
group.
Conclusion: In selected cases, a hysterectomy may be an effective means to either re-
duce or eliminate tumor bulk. Primary hysterectomy should mainly be considered 
in older patients with localized disease and no desire to preserve fertility, whereas 
patients with chemotherapy-resistant disease may benefit from additional hysterec-
tomy, especially when disease is localized. For patients with widespread metastatic 
disease, the benefit of hysterectomy lies in the removal of chemotherapy-resistant 
tumor bulk with subsequent effect on survival.
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introDuCtion
Gestational trophoblastic disease (GTD) comprises a spectrum of conditions ranging 
from the pre-malignant complete (CHM) and partial (PHM) hydatidiform moles to 
the malignant choriocarcinoma and placental site trophoblastic tumor (PSTT) 1,2. The 
term gestational trophoblastic neoplasia (GTN) has been applied collectively to the 
malignant counterparts 3. Post-molar GTN occurs in approximately 15-20% of com-
plete hydatidiform moles and 0.5-1% of partial hydatidiform moles, characterized by 
plateauing or rising blood human chorionic gonadotrophin concentration (hCG). 
The management of GTN can be considered a success story of modern medicine. 
Historically, hysterectomy was the treatment of choice in patients with GTN. In the 
early 1960s, outcome was poor with 5-year survival rate after hysterectomy of 41% 
in non-metastatic disease and 19% in metastatic disease 4. The introduction of che-
motherapy, recognition of risk factors allowing for individualized treatment and use 
of sensitive hCG assays as a valuable marker for monitoring disease are the main 
reasons for current treatment success 5. Today, trophoblastic neoplasias are among 
the most curable malignancies, with cure rates approaching 90%, even in the pres-
ence of widespread disease 1,6,7. 
Despite the excellent success of chemotherapy in most patients, problems related 
to chemo-resistant disease and toxicity have led to reconsideration of the use of 
hysterectomy in individualized cases. Hysterectomy with or without lymph node 
dissection remains the treatment of choice for PSTT, as these tumors appear fairly 
chemo-resistant with a propensity for lymphatic spread 8-11. Secondary hysterectomy 
and metastasectomy (ie pulmonary resection, craniotomy, liver lobe resection) play 
a significant role in the management of chemo-resistant disease 1,12-14. Response to 
first-line chemotherapy is estimated to be incomplete in 25% of low-risk patients and 
20% of high-risk patients respectively 15. Furthermore, surgical procedures may be 
inevitable in case of life-threatening hemorrhage 16,17. A primary hysterectomy may 
be considered for perimenopausal patients without the desire to preserve fertility, 
ideally resulting in a reduction of administered cycles of chemotherapy and a subse-
quent reduction of toxic effects 13,17. In addition, although the current study is mainly 
focused on GTN, it should be noted that hysterectomy may sometimes be considered 
as primary treatment for GTD 18.
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Although several authors have assessed the role of hysterectomy in GTN, it generally 
involved small-size studies 4,12,13,17. Apprehension of the possible benefits of hysterec-
tomy is needed to facilitate the individual treatment decision in daily practice. In the 
present study, we evaluated indications for and outcome of hysterectomy in patients 
with GTN in a large nation-wide cohort. Considering the wide timeframe of our cohort, 
possible differences in indication for and outcome after hysterectomy were evaluated 
over time. 
MAtEriAls AnD MEthoDs
Patients
Since 1977 patients with GTD are registered at the Dutch Central Registry for hydatidi-
form moles at the Radboud University Medical Center, Nijmegen. This voluntary reg-
istry serves mainly as an epidemiological database and provides an hCG assay service 
for gynecologists nationwide. Patients with GTN are treated in referral hospitals and 
are discussed in the Dutch Working Party on Trophoblastic Disease. Data on patients 
with hysterectomy performed between 1977 and 2012 were collected from the data-
base and records of the Dutch Working Party meetings. Moreover, hospital records of 
all patients were reviewed for additional information. For each patient, we reviewed 
demographic characteristics, FIGO 2000 prognostic scoring criteria, indication for sur-
gery, treatment regimen, response to treatment, histological diagnosis and follow-up 
of at least two-years. Nine patients with PSTT were excluded from further analysis, 
since management and prognosis for these patients differs from other GTN patients 
8-10. One hundred and nine patients were eligible for further analysis (Figure 1). A com-
parison between patients with hysterectomy performed before and after 1995 was 
made, to evaluate how indications for hysterectomy and outcome after hysterectomy 
may have changed over time. The cutoff point was chosen arbitrary, resulting in two 
equal timeframes.
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Definitions
GTN was diagnosed according to the FIGO 2000 criteria (ie, mola hydatidosa with 
serum hCG plateauing for three consecutive weeks or increasing over a period of two 
consecutive weeks). In line with the Dutch guidelines, the following criterion was 
added to this definition: at least one of the values should exceed the 95th percentile 
of an hCG normogram of uneventful hCG decline as constructed by Yedema et al. 
19. Chemotherapy-resistant disease was defined as a plateauing or rising serum hCG 
concentration in three consecutive weekly measurements. Resistance to therapy 
was assessed by serum hCG measurements, using an in-house developed radioim-
munoassay (RIA) that detects both intact hCG and free β-subunit 20. hCG follow-up 
was undertaken weekly until serum hCG was normal and then monthly until one 
year after completion of single-agent chemotherapy or two years after completion of 
multi-agent chemotherapy.
Protocols for the management of Gtn
To select the appropriate treatment, all patients were classified into low- or high-risk 
disease using the Dutch risk classification. Risk classification with this system shows an 
extensive overlap with the more widely used FIGO 2000 21. Low-risk patients received 
single-agent methotrexate (MTX) with folinic acid rescue (50 mg intramuscular MTX 
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on days 1, 3, 5, and 7 and folinic acid 15 mg orally on days 2, 4, 6, and 8). Between 
1977 and 1990 high-risk patients and patients with chemo-resistant disease were 
treated with multi-agent chemotherapy in various effective regimens. Since 1990, the 
EMA/CO chemotherapeutic regimen, consisting of etoposide, methotrexate, actino-
mycin D alternating weekly with cyclophosphamide and vincristine is recommended 
as treatment of choice in patients developing resistance, unmanageable toxicity or 
high-risk disease 22,23. 
statistical analysis
To evaluate the therapeutic effect of hysterectomy, a comparison between patients 
with hysterectomy and patients without hysterectomy was performed. Due to the 
retrospective nature of this cohort study, patients were not randomized prior to hys-
terectomy. To reduce the bias of possible confounding factors, we used the propensity 
score matching method as described by Austin 24. In this analysis, patients treated with 
hysterectomy were matched one-to-one with patients without hysterectomy treat-
ment, based on maternal age, antecedent pregnancy, interval between evacuation 
and treatment, and pre-treatment serum hCG. The performance of the propensity 
score model was evaluated by assessing whether any important relationship between 
both groups and the covariates remained after adjustment. With the excellent prog-
nosis of GTN today, treatment duration and number of chemotherapy cycles needed 
to reach complete remission instead of survival were the outcome variables of choice.
Differences in parametrical data were assessed by two-tailed students t test. Non-
parametric data were analyzed with two-tailed Mann-Whitney U test and Fisher-
Freeman-Halton Test. Analyses were carried out using Microsoft Office Excel 2007 
and SPSS for Windows (version 22). 
rEsults
From 1977 to 2012, a total of 713 patients diagnosed with GTN were registered at 
the Dutch Central Registry for Hydatidiform Moles or discussed at the Dutch Working 
derwent hysterectomy as part of their management for GTN. For 28 of these patients 
(25.7%), hysterectomy was performed with uni- or bilateral salpingo-oophorectomy.
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Median age at start of treatment was 36 years (minimum 20, maximum 60), with 
the majority of cases classified as low-risk disease (74.3%), post-molar GTN (73.5%) 
and disease confined to the uterus (65.1%). Demographic and clinical characteristics 
for patients with localized disease and patients with metastatic disease are shown in 
Table 1. Metastatic disease predominantly involved lung or vaginal involvement. In 8 
table 1. Demographic and clinical characteristics of all patients with hysterectomy performed 
localized disease
n=71
Metastatic 
disease n=38
total Cohort
n=109
Median (min-max) Median (min-max) P Median (min-max)
Age (Years)a 37.0 (24-60) 34.0 (20-52) 36.0 (20-60)
Interval months from index pregnancy 1.0 (0-46) 1.0 (0-24) 1.0 (0-46)
Pretreatment 10log Serum hCG (ng/
mL)
3.7 (1.04-5.73) 4.6 (0.3-5.95) 3.9 (0.3-5.95)
Number (%) Number (%) P Number (%)
Antecedent pregnancy <0.01
Term 6 (8.5%) 8 (21.1%) 14 (12.8%)
Hydatidiform Mole 62 (87.3%) 18 (47.4%) 80 (73.5%)
Abortion/unknown 3 (4.2%) 12 (31.5%) 15 (13.7%)
Site of metastasis <0.01
None 71 (100.0%) - 71 (65.1%)
Vagina or Lung - 25 (65.8%) 25 (22.9%)
Other metastasis b - 13 (34.2%) 13 (11.9%)
Risk classification <0.01
Low-risk 64 (90.1%) 17 (44.7%) 81 (74.3%)
High-risk 7 (9.9%) 20 (52.6%) 27 (24.8%)
Unkown - 1 (2.6%) 1 (0.9%)
Metastasectomy <0.01
Yes - 8 (21.1%) 8 (7.3%)
No 71 (100.0%) 30 (78.9%) 101 (92.7%)
Pathology findings <0.01
Negative for trophoblastic disease 6/63 (9.5%) 8/35 (22.9%) 14/98 (14.3%)
Number (%) Number (%) P Number (%)
Follow-up a
Complete remission following 
hysterectomy c
Complete remission after finishing 
treatment
48/71 (67.6%)
66/68 (97.1%)
6/38 (15.8%)
28/35 (73.7%)
<0.05
<0.01
54/109 (49.5%)
94/103 (91.3%)
Complete remission after 6 months 43/45 (95.6%) 20/27 (74.1%) <0.05 63/72 (87.5%)
Complete remission after 12 months 35/38 (92.1%) 18/25 (47.4%) <0.05 53/63 (84.1%)
Complete remission after 24 months 27/30 (90.0%) 16/23 (42.1%)   0.08 43/53 (81.1%)
Mortality 2/67 (3.0%) 7/34 (20.6%) 9/101 (8.9%)
a Follow-up is shown for all patients where follow-up information was available
b Other metastasis may be localized in kidney, gastro-intestinal tract, liver and or brain
c Compete remission after hysterectomy, achieved without further chemotherapy or surgery
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cases (7.3%) a metastasectomy was additionally performed, mainly involving resec-
tion of pulmonary metastases. Nine patients (8.9%) died as a result of their GTN. In 
six of these cases, brain metastases causing intracranial hemorrhage was the eventual 
cause of death, other causes included sepsis following severe myelosuppression (n=1) 
and hypovolemic shock due to severe intra-abdominal hemorrhage (n=2). Twelve 
months after completion of treatment, 84.1% of patients with follow-up information 
available still showed no signs of recurrent disease. 
Histological findings of the resected uterine specimen were negative for gestational 
trophoblastic disease in 14.3% of cases (Table 1). Severe complications as a result of 
the surgical procedure occurred in 4 cases (3.5%), consisting of cardiac symptoms 
requiring re-admittance (n=1), severe hemorrhage requiring surgical re-intervention 
(n=2) and post-operative infection requiring re-intervention (n=1). 
In Table 2, a comparison of patient characteristics and outcome between patients with 
hysterectomy performed before and after 1995 is shown. When compared to patients 
in the first cohort, patients in the second cohort presented with a significantly older 
age (median 34.8 and 41.2 respectively, p<0.01) but comparable pre-treatment serum 
hCG (median 3.8 ng/mL and 4.0 ng/mL respectively, p=0.68) and interval (median 
both 1.0 months, p=0.20). The indications for hysterectomy and the complete remis-
table 2. Characteristics, treatment indication and outcome between first and second cohort com-
pared
First Cohort a 
(n=58)
second cohort b
(n=51)
Median (min-max) Median (min-max) P 
Age (years) 34.8 (20-60) 41.2 (25-55) <0.01 
Interval months from index pregnancy 1.0 (0-46) 1.0 (0-21)   0.20
Pretreatment 10log Serum hCG (ng/mL) 3.8 (0.3-6.0) 4.0 (1.0-5.7)   0.68
number (%) number (%)
High-risk disease 40/81 (49.4%) 17/27 (63.0%)   0.19
indication hysterectomy   0.31
Primary treatment 13 (22.4%) 17 (33.3%)
Chemo-resistant disease 39 (67.2%) 27 (52.9%)
Hemorrhage 6 (10.3%) 7 (13.7%)
Complete remission after hysterectomy 25/51 (49.0%) 29/48 (60.4%)   0.16
a First cohort represents all patients treated with hysterectomy before 1995
b Second cohort refers to all patients treated with hysterectomy from 1995 onwards
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sion rate following hysterectomy were not different between the first and second 
cohort (p=0.31 and p=0.16 respectively). 
The three main reasons for hysterectomy were primary definitive treatment, 
chemo-resistant disease and life-threatening hemorrhage, which mainly involved 
intra-abdominal hemorrhage. Overall, 48 of the 71 patients with localized disease 
(67.6%) achieved complete remission after hysterectomy. The indication-specific 
response to hysterectomy for patients with localized disease is shown in Figure 2a. 
Complete remission after primary hysterectomy was seen in 47.8% of patients with 
a)
 
Figure 2. Indication and effect of hysterectomy for patients with GTN, a) patients with localized 
disease, b) patients with metastatic disease. The classification between localized and metastatic 
disease was made at start of treatment. Some of these patients may have presented with occult 
metastatic disease later in their treatment course.  
a) 
Hysterectomy patients with localized disease
N=71
Primary treatment
N=23 (32.4%)
Chemoresistant disease
N=43 (60.6%)
Life-threatening
hemorrhage
N=5 (7.0%)
Additional treatment 
required after hysterectomy
N=12 (52.2%)
Complete remission after 
hysterectomy
N=4 (80.0%)
Indication for hysterectomy
Single-agent resistant
N=19 (44.2%)
Multi-agent resistant
N=24 (55.8%)
Complete remission after 
hysterectomy
N=18 (94.7%)
Complete remission after 
hysterectomy
N=14 (58.3%)
Complete remission after 
hysterectomy
N=11 (47.8%)
Additional treatment 
required after hysterectomy
N=1 (20.0%)
Additional treatment 
required after hysterectomy
N=1 (5.3%)
Additional treatment 
required after hysterectomy
N=10 (41.7%)
Mortality
N=2
 
 
b) 
 
hysterectomy patients with metastatic disease
N=38
Primary treatment
N=7 (18.4%)
Chemoresistant disease
N=23 (60.5%)
Life-threatening 
hemorrhage
N=8 (21.1%)
Additional treatment 
required after 
hysterectomy
N=7 (100.0%)
Complete remission 
after hysterectomy
N=2 (25.0%)Complete remission 
after hysterectomy 
N=4 (17.4%)
Indication for hysterectomy
Complete remission after 
hysterectomy
N=0 (0.0%)
Additional treatment 
required after 
hysterectomy
N=19 (82.6%)
Additional treatment 
required after 
hysterectomy
N=6 (75.0%)
Mortality
N=2
Mortality
N=5
 
 
b)
 
Figure 2. Indication and effect of hysterectomy for patients with GTN, a) patients with localized 
disease, b) patients with metastatic disease. The classification between localized and metastatic 
disease was made at start of treatment. Some of these patients may have presented with occult 
metastatic disease later in their treatment course.  
a) 
Hysterectomy patients with localized disease
N=71
Primary treatment
N=23 (32.4%)
Chemoresistant disease
N=43 (60.6%)
Life-threatening
hemorrhage
N=5 (7.0%)
Additional treatment 
required after hysterectomy
N=12 (52.2%)
Complete remission after 
hysterectomy
N=4 (80.0%)
Indication for hysterectomy
Single-agent resistant
N=19 (44.2%)
Multi-agent resistant
N=24 (55.8%)
Complete remission after 
hysterectomy
N=18 (94.7%)
Complete remission after 
hysterectomy
N=14 (58.3%)
Complete remission after 
hysterectomy
N=11 (47.8%)
Additional treatment 
required after hysterectomy
N=1 (20.0%)
Additional treatment 
required after hysterectomy
N=1 (5.3%)
Additional treatment 
required after hysterectomy
N=10 (41.7%)
Mortality
N=2
 
 
b) 
 
hysterectomy patients with metastatic disease
N=38
Primary treatment
N=7 (18.4%)
Chemoresistant disease
N=23 (60.5%)
Life-threatening 
hemorrhage
N=8 (21.1%)
Additional treatment 
required after 
hysterectomy
N=7 (100.0%)
Complete remission 
after hysterectomy
N=2 (25.0%)Complete remission 
after hysterectomy 
N=4 (17.4%)
Indication for hysterectomy
Complete remission after 
hysterectomy
N=0 (0.0%)
Additional treatment 
required after 
hysterectomy
N=19 (82.6%)
Additional treatment 
required after 
hysterectomy
N=6 (75.0%)
Mortality
N=2
Mortality
N=5
 
 
Figure 2. Indication and effect of hysterectomy for patients with GTN, a) patients with localized 
disease, b) patients with metastatic disease. The classification between localized and metastatic 
disease was made at start of treatment. Some of these patients may have presented with occult 
metastatic disease later in their treatment course.
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localized disease. Complete remission after hysterectomy occurred more frequently 
in single-agent resistant patients than in multi-agent-resistant patients (94.7% and 
58.3%, p<0.05).
When patients presented with metastatic disease, no patients achieved complete 
remission with primary hysterectomy alone, whereas only 6 out of 31 (19.4%) pa-
tients achieved complete remission after hysterectomy was done for chemo-resistant 
disease or life-threatening hemorrhage. The indication-specific response to hysterec-
tomy for patients with metastatic disease is shown in Figure 2b.
In Table 3 treatment duration and number of chemotherapy cycles is compared be-
tween patients with localized disease, treated with primary hysterectomy and a one-
to-one matched control group primarily treated with chemotherapy. Four subjects 
who did not have a reasonable match were excluded from further analysis. When 
compared to the matched control group, patients treated with primary hysterectomy 
for localized disease had a significantly shorter treatment duration (mean 8.0 weeks 
and 3.2 weeks respectively, p=0.01) and lower number of administered chemotherapy 
cycles (mean 5.8 and 1.5 respectively, p<0.01). To evaluate the performance of the 
propensity scoring model, a comparison of the covariates involved in the matching 
procedure was made between the study group and matched control group. The co-
variates did not significantly differ between both groups. 
table 3. Comparison of treatment duration and number of chemotherapy cycles between pa-
tients treated with primary hysterectomy for localized disease and a matched control group
Primary hysterectomy 
performed
n=19 
Matched Control 
group
n=19
number number P
single-Agent administered 8/19 19/19 <0.01
Multi-Agent administered 1/19 1/19 1.00
Mean (sd) Mean (sd) P
treatment duration (weeks) 3.2 (3.2) 8.0 (4.8) 0.01
number of courses 
      Total 1.5 (2.6) 5.8 (2.9) <0.01
      Single-Agent 1.2 (2.1) 5.4 (2.1) <0.01
      Multi-Agent 0.2 (0.9) 0.4 (1.8) 0.69
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For patients with a hysterectomy performed to control chemo-resistant disease or 
intra-abdominal hemorrhage, identification of a matched control group through 
propensity matching was not feasible, as their clinical characteristics widely differed. 
DisCussion
In the present study we explored the added value of hysterectomy in patients with 
gestational trophoblastic neoplasia. Approximately one out of six GTN patients (16.5%) 
required hysterectomy during the course of their treatment to either remove tumor 
bulk or treat complications. After hysterectomy, complete remission was achieved 
in 67.6% of patients with localized disease and in 15.8% of patients with metastatic 
disease. Primary hysterectomy resulted in complete remission in 47.8% of cases 
when disease was localized. Comparison with a matched control group showed that 
a shorter treatment duration and lower number of chemotherapy cycles was needed 
to reach complete remission after primary hysterectomy. 
Considering the wide timeframe of our cohort, possible differences in clinical char-
acteristics, treatment indications and outcome were compared between the first 
and second cohort. In line with other studies, the groups had generally comparable 
characteristics with a similar distribution of treatment indications 25.
Other centers have published their experience on the management of GTN using hys-
terectomy with incidence ranging from 17% to 32% 25-30. Higher incidence rates likely 
result from differences in available resources for treatment and follow-up, as some 
studies were conducted in developing countries 27. In line with these other studies, 
main indications for hysterectomy in our patients with GTN were primary definitive 
treatment, chemo-resistant disease and life-threatening hemorrhage 12,25,27,28.
Since patients with metastatic disease present with distinct clinical features and a 
slightly less favorable prognosis than patients with localized disease, both groups were 
analyzed separately. Complete remission following hysterectomy was incidentally 
seen in patients with metastatic disease, in general the procedure was however less 
effective in patients with metastatic disease than in patients with localized disease. 
Chapter 584
Therefore, information on extra-uterine disease involvement seems important while 
considering treatment with hysterectomy. 
Primary hysterectomy has been suggested in perimenopausal patients when fertility 
preservation is not required. Ideally this would result in a reduction of chemotherapy 
cycles needed to achieve complete remission. Reported results on the actual ben-
efits are however conflicting 13,17,31,32. In general the procedure is expected to be 
most beneficial in patients with localized disease, but primary hysterectomy may 
also be considered in selected patients with high-risk metastastic GTN and limited 
extra-uterine burden 33,34. Hammond et al. reported that elective initial hysterectomy 
significantly reduced the duration of hospitalization and the number of chemotherapy 
cycles needed to achieve complete remission in both patients with and without me-
tastases 31. In the present study 47.8% of patients with localized disease had complete 
sustained remission following primary hysterectomy alone. When compared to a 
matched control group, treatment with primary hysterectomy resulted in a shorter 
treatment duration and lower number of chemotherapy cycles needed to reach 
complete remission, when disease was localized. Considering the performance of 
salpingo-oophorectomy in some patients, it should be noted that this procedure may 
have simultaneously removed occult metastatic disease. In patients with metastatic 
disease, primary hysterectomy was less effective and additional chemotherapeutic 
treatment was always indicated. Primary hysterectomy should therefore mainly be 
considered in patients over forty years of age, without extra-uterine burden or desire 
to preserve fertility. 
In selected patients with persistent or recurrent high-risk GTN, hysterectomy is used 
to remove foci of chemotherapy-resistant disease 33. In some cases, hysterectomy can 
reduce or eliminate the need for further chemotherapeutic treatment 31,35-37. When 
disease was confined to the uterus, 94.7% of single-agent resistant cases was fully 
salvaged by hysterectomy, whereby the more aggressive multi-agent regimen could 
be avoided. Examining the role of hysterectomy in patients with metastatic disease, 
revealed a less favorable effect of hysterectomy, with 17.4% being fully salvaged with 
hysterectomy. 
Usually, the presence of active disease outside the uterus will require additional man-
agement, though incidentally due to previous chemotherapeutic treatment these foci 
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may have resolved. As mentioned before, patients with widespread metastatic disease 
represent a selected group with recurrent or persistent chemo-resistant disease. Fatal 
outcome as a consequence of the disease, is predominantly seen in this particular 
group. Therefore, the primary benefit of hysterectomy in patients with metastatic 
disease is not a decline in administered cycles of multi-agent chemotherapy, but a 
reduction of chemo-resistant tumor bulk with subsequent effect on survival. 
Finally, hysterectomy may play a role in therapy for high-risk disease as a means of 
dealing with life-threatening complications, such as intra-abdominal or vaginal hem-
orrhage 33. Thirteen patients (11.9%) in our total study cohort required hysterectomy 
to control hemorrhage, mainly intra-abdominal.  These patients can present with 
excessive bleeding and may therefore be haemodynamically unstable.
In the present study, no histological evidence of active trophoblastic disease in the 
uterus was found in 14.3% of cases. This was predominantly apparent in patients 
with chemo-resistant disease, when cure appeared to be challenging. In some of 
these cases, tumor foci might have been present on imaging as trophoblastic tumors 
have slow radiologic resolution, particularly in bigger masses 38. Although it is im-
perative to perform imaging and assess the presence of uterine disease, one should 
therefore keep in mind that the volume of a trophoblastic tumor may not represent 
the proportion of viable cells present 2,39. Positron emission tomography-computer 
tomography (PET CT) scanning could be a helpful tool to discriminate active versus 
necrotic tumors 40.
Women treated with hysterectomy represent a specific subset of patients and may 
not represent the average patient with GTN. Depending on the indication for surgery, 
these patients may present with larger tumor bulk when treated for chemo-resistant 
disease or poorer physical fitness when presented with disease related complica-
tions such as hemorrhage. To enable the evaluation of possible therapeutic effects 
of hysterectomy, we strived to perform a comparison between patients treated with 
hysterectomy and a matched control group. Unfortunately, due to the wide differ-
ences in clinical characteristics, no consistent control group could be matched to the 
hysterectomy patients with chemo-resistant disease or hemorrhage and patients with 
metastatic disease who were primarily treated with hysterectomy.
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ConClusion
Despite the undoubted effectiveness of chemotherapeutic treatment in GTN, prob-
lems related to toxicity of chemotherapy and chemo-resistant disease have led to 
reconsideration of the use of hysterectomy. In selected cases, a hysterectomy may 
be an effective treatment to either reduce or eliminate tumor bulk. Upon decision a 
number of drawbacks should however be considered. 
Although complete remission following hysterectomy was incidentally reported in pa-
tients with metastatic disease, in general the procedure was less effective in patients 
with metastatic disease than in patients with localized disease. For patients with 
widespread metastatic disease however, the benefit of hysterectomy generally lies in 
the removal of chemotherapy-resistant tumor bulk to improve survival. Furthermore, 
due to prominent uterine vasculature, patients with GTN are at increased risk of 
life-threatening hemorrhage during hysterectomy 17 and initiation of chemotherapy 
may be delayed should postoperative complications occur 27. Additionally, given the 
number of patients who need further chemotherapeutic treatment following hyster-
ectomy, all patients still need to be monitored with serum hCG measurements during 
follow-up.
87The added value of hysterectomy in the management of gestational trophoblastic neoplasia
5
rEFErEnCEs
 1. Seckl MJ, Sebire NJ, Fisher RA, et al. Gestational trophoblastic disease: ESMO Clinical 
Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 suppl 6: 
vi39-50.
 2. Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presenta-
tion and diagnosis of gestational trophoblastic disease, and management of hydatidiform 
mole. Am J Obstet Gynecol 2010; 203(6): 531-9.
 3. Froeling FE, Seckl MJ. Gestational trophoblastic tumours: an update for 2014. Curr Oncol 
Rep 2014; 16(11): 408.
 4. Brewer JI, Smith RT, Pratt GB. Choriocarcinoma. Absolute 5 year survival rates of 122 
patients treated by hysterectomy. Am J Obstet Gynecol 1963; 85: 841-3.
 5. Feng F, Xiang Y, Li L, Wan X, Yang X. Clinical parameters predicting therapeutic response 
to surgical management in patients with chemotherapy-resistant gestational tropho-
blastic neoplasia. Gynecol Oncol 2009; 113(3): 312-5.
 6. Soper JT. Gestational trophoblastic disease. Obstet Gynecol 2006; 108(1): 176-87.
 7. Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. 
Gynecol Oncol 2009; 112(3): 654-62.
 8. Papadopoulos AJ, Foskett M, Seckl MJ, et al. Twenty-five years’ clinical experience with 
placental site trophoblastic tumors. J Reprod Med 2002; 47(6): 460-4.
 9. Hassadia A, Gillespie A, Tidy J, et al. Placental site trophoblastic tumour: clinical features 
and management. Gynecol Oncol 2005; 99(3): 603-7.
 10. Schmid P, Nagai Y, Agarwal R, et al. Prognostic markers and long-term outcome of 
placental-site trophoblastic tumours: a retrospective observational study. Lancet 2009; 
374(9683): 48-55.
 11. Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet 2010; 
376(9742): 717-29.
 12. Doumplis D, Al-Khatib K, Sieunarine K, et al. A review of the management by hysterec-
tomy of 25 cases of gestational trophoblastic tumours from March 1993 to January 2006. 
BJOG 2007; 114(9): 1168-71.
 13. Doll KM, Soper JT. The role of surgery in the management of gestational trophoblastic 
neoplasia. Obstet Gynecol Surv 2013; 68(7): 533-42.
 14. Newlands ES, Holden L, Seckl MJ, McNeish I, Strickland S, Rustin GJ. Management of 
brain metastases in patients with high-risk gestational trophoblastic tumors. J Reprod 
Med 2002; 47(6): 465-71.
 15. Lurain JR, Nejad B. Secondary chemotherapy for high-risk gestational trophoblastic 
neoplasia. Gynecol Oncol 2005; 97(2): 618-23.
 16. Lurain JR. Gestational trophoblastic disease II: classification and management of gesta-
tional trophoblastic neoplasia. Am J Obstet Gynecol 2011; 204(1): 11-8.
 17. Hanna RK, Soper JT. The role of surgery and radiation therapy in the management of 
gestational trophoblastic disease. Oncologist 2010; 15(6): 593-600.
 18. Elias KM, Shoni M, Bernstein M, Goldstein DP, Berkowitz RS. Complete hydatidiform 
mole in women aged 40 to 49 years. J Reprod Med 2012; 57(5-6): 254-8.
 19. Yedema KA, Verheijen RH, Kenemans P, et al. Identification of patients with persistent 
trophoblastic disease by means of a normal human chorionic gonadotropin regression 
curve. Am J Obstet Gynecol 1993; 168(3 Pt 1): 787-92.
Chapter 588
 20. Thomas CM, Segers MF, Houx PC. Comparison of the analytical characteristics and clini-
cal usefulness in tumour monitoring of fifteen hCG(-beta) immunoassay kits. Ann Clin 
Biochem 1985; 22 ( Pt 3): 236-46.
 21. Eysbouts YK, Massuger L, Thomas C, et al. Dutch Risk Classification and FIGO 2000 for 
Gestational Trophoblastic Neoplasia Compared. Int J Gynecol Cancer 2016.
 22. Lok CA, Ansink AC, Grootfaam D, van der Velden J, Verheijen RH, ten Kate-Booij MJ. 
Treatment and prognosis of post term choriocarcinoma in The Netherlands. Gynecol 
Oncol 2006; 103(2): 698-702.
 23. van de Kaa CA, Schijf CP, de Wilde PC, Hanselaar AG, Vooijs PG. The role of deoxyribo-
nucleic acid image cytometric and interphase cytogenetic analyses in the differential 
diagnosis, prognosis, and clinical follow-up of hydatidiform moles. A report from the 
Central Molar Registration in The Netherlands. Am J Obstet Gynecol 1997; 177(5): 1219-
29.
 24. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of 
Confounding in Observational Studies. Multivariate behavioral research 2011; 46(3): 
399-424.
 25. Clark RM, Nevadunsky NS, Ghosh S, Goldstein DP, Berkowitz RS. The evolving role of 
hysterectomy in gestational trophoblastic neoplasia at the New England Trophoblastic 
Disease Center. J Reprod Med 2010; 55(5-6): 194-8.
 26. Pires LV, Uberti EM, Fajardo Mdo C, et al. Role of hysterectomy in the management of 
patients with gestational trophoblastic neoplasia: importance of receiving treatment in 
reference centers. J Reprod Med 2012; 57(7-8): 359-68.
 27. Cagayan MS, Magallanes MS. The role of adjuvant surgery in the management of gesta-
tional trophoblastic neoplasia. J Reprod Med 2008; 53(7): 513-8.
 28. Ghaemmaghami F, Ashrafgangooei T, Gillani MM, Mosavi A, Behtash N. Major surgeries 
performed for gestational trophoblastic neoplasms in a teaching hospital in Tehran, Iran. 
J Gynecol Oncol 2011; 22(2): 97-102.
 29. El-Lamie IK, Shehata NA, Abou-Loz SK, Ei-Lamie KI. Experience of the Gynecologic Oncol-
ogy Unit at Ain Shams University in the treatment of gestational trophoblastic tumors. 
Int J Gynecol Cancer 2000; 10(6): 488-96.
 30. Fulop V, Szigetvari I, Szepesi J, Vegh G, Zsirai L, Berkowitz RS. The Role of Surgery in 
the Management of Gestational Trophoblastic Neoplasia The Hungarian Experience. J 
Reprod Med 2016; 61(5-6): 197-204.
 31. Hammond CB, Weed JC, Jr., Currie JL. The role of operation in the current therapy of 
gestational trophoblastic disease. Am J Obstet Gynecol 1980; 136(7): 844-58.
 32. Jones WB, Lewis JL, Jr. Integration of surgery and other techniques in the management 
of trophoblastic malignancy. Obstet Gynecol Clin North Am 1988; 15(3): 565-76.
 33. Lurain JR, Singh DK, Schink JC. Role of surgery in the management of high-risk gestational 
trophoblastic neoplasia. J Reprod Med 2006; 51(10): 773-6.
 34. Fang J, Wang S, Han X, An R, Wang W, Xue Y. Role of adjuvant hysterectomy in manage-
ment of high-risk gestational trophoblastic neoplasia. Int J Gynecol Cancer 2012; 22(3): 
509-14.
 35. Suzuka K, Matsui H, Iitsuka Y, Yamazawa K, Seki K, Sekiya S. Adjuvant hysterectomy in 
low-risk gestational trophoblastic disease. Obstet Gynecol 2001; 97(3): 431-4.
 36. Lehman E, Gershenson DM, Burke TW, Levenback C, Silva EG, Morris M. Salvage surgery 
for chemorefractory gestational trophoblastic disease. J Clin Oncol 1994; 12(12): 2737-
42.
89The added value of hysterectomy in the management of gestational trophoblastic neoplasia
5
 37. Pisal N, North C, Tidy J, Hancock B. Role of hysterectomy in management of gestational 
trophoblastic disease. Gynecol Oncol 2002; 87(2): 190-2.
 38. Bagshawe KD. Risk and prognostic factors in trophoblastic neoplasia. Cancer 1976; 38(3): 
1373-85.
 39. Ngan HY, Bender H, Benedet JL, et al. Gestational trophoblastic neoplasia, FIGO 2000 
staging and classification. Int J Gynaecol Obstet 2003; 83 suppl 1: 175-7.
 40. Brown J, Naumann RW, Seckl MJ, Schink J. 15years of progress in gestational trophoblas-
tic disease: Scoring, standardization, and salvage. Gynecol Oncol 2016.
6
Chapter 6
Dutch r isk c la ssification and FIGO 
2000 for gestational trophoblastic 
neoplasia compared 
 
 
 
 
 
Y.K. Eysbouts
L.F.A.G. Massuger
C.M.G. Thomas
D. Short
R. Harvey
N.J. Sebire
B. Kaur
N. Sawar
F.C.G.J. Sweep
M.J. Seckl
Int J Gynecol Cancer.2016 Nov; 26(9):1712-1716
Chapter 692
AbstrACt
objective: Over the years there has been a wide variety of classification systems in use 
worldwide to stratify patients between single versus multi-agent chemotherapy, 
hindering comparison of international research results. Present study presents a 
retrospective comparison of the FIGO 2000 and Dutch risk classification system for 
gestational trophoblastic neoplasia.  
Methods: All patients diagnosed with GTN between January 2003 and December 
2012 at the trophoblastic disease center in London were retrospectively scored 
according to the Dutch Classification system (n=813)
results: An extensive overlap between both scoring systems was seen, even though 
items and relative value of items was quite distinct. The Dutch system seems to be 
simpler and easier to apply in all situation, a degree of overtreatment can however 
be presumed with the use of either system. 
Conclusions: Whilst it is likely that outcome is indeed affected by the individual 
factors used in both systems, many factors relate to tumor bulk and may not be 
independently prognostic. We therefore believe that further refinement of the 
classification systems and their underlying prognostic items plus any new items 
that appear promising would be useful.
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introDuCtion
Gestational trophoblastic disease (GTD) comprises a group of diseases, ranging from 
the pre-malignant partial (PHM) and complete hydatidiform moles (CHM) to malig-
nant choriocarcinoma (CC), placental site trophoblastic tumor (PSTT) and epithelioid 
trophoblastic tumor (ETT) 1,2. Nowadays GTN are among the most curable malignan-
cies, with cure rates approaching 90%, even in the presence of metastases 2-5. 
As clinical scoring systems predict the potential for resistance to single-agent chemo-
therapy with great accuracy, classification of GTN patients with recognized prognostic 
criteria and subsequent selection of appropriate treatment is now widely accepted 
6-8. Low-risk patients are often treated with methotrexate combined with folinic acid, 
with actinomycin D as an acceptable alternative in case of toxicity or resistance. High-
risk patients should be treated with a multi-agent chemotherapy regimen. The EMA/
CO protocol consisting of etoposide, methotrexate combined with folinic acid and 
actinomycin D alternating weekly with cyclophosphamide and vincristine has proven 
efficacy in primary treatment for high-risk patients 9-15. Patients with PSTT are classi-
fied separately as first line treatment comprises hysterectomy due to relatively chemo 
resistant disease 16-19.
Due to wide variety of classification systems worldwide however, it has been difficult 
to evaluate patient care and perform a meaningful comparison of management out-
comes 6,7,20,21. It is likely that some patients have been either under- or overtreated, 
resulting in increased chemo resistance or elongation of treatment and treatment 
toxicity, respectively. 
The prognostic scoring system Bagshawe suggested in 1976 considered different 
weights for various prognostic factors. It provided the basis for the WHO classifica-
tion system, Charing Cross system and later the FIGO 2000 8,22,23. The FIGO 2000 is a 
revised staging and classification system comprising a number of prognostic factors as 
shown in Table 1. Patients with a score of 0-6 are considered low-risk for developing 
resistance to single-agent chemotherapy, a score of 7 or higher is considered high-risk 
7,20,24. The FIGO 2000 has gained wide acceptance worldwide and has been field tested 
in Sheffield UK 22. 
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In 1983, the Dutch Working Party on Trophoblastic Disease proposed a classification 
system using a number of absolute criteria for dividing patients into low- or high-risk 
for developing single-agent resistance, including antecedent term pregnancy and pre-
vious chemotherapeutic failure, shown in Table 28,25. It relies on absolute divergence 
with the use of a confined number of criteria, resulting in a relatively straightforward 
system. The system is still employed today due to the use of a small set of easily 
retrievable factors and the assumption that serious prognostic factors such as liver 
involvement and interval are taken as absolute criteria for high-risk treatment 25.
To date, an appraisal of the Dutch classification system in comparison to the FIGO 
2000 has not been performed. To validate and improve management of GTN how-
ever, it is essential to reach consensus on scoring systems and treatment protocols 
subsequently. 
table 1. FIGO 2000 Classification system for GTN
score 0 1 2 4
Age (years) <40 ≥40 - -
Antecedent pregnancy Mole Abortion Term -
Interval from index pregnancy (months) <4 4-6 7-12 ≥13
Pre-treatment serum hCG (IU/L) <103 < 104 < 105 ≥105
Largest tumor size (cm) <3 3-4 ≥5 -
Site of metastases Lung Spleen, kidney Gastro-intestinal Liver, brain
Number of metastases - 1-4 5-8 >8
Previous failed chemotherapy - - Single drug Multi drug
A total score of 0-6 = low-risk; score ≥ 7 = high-risk
table 2. Dutch classification system for GTN
risk group Criteria
Low-risk 1. Antecedent pregnancy was a mole or miscarriage
2. Metastases  confined to vagina or lungs
3. No previous failed chemotherapy
4.  Interval from end of index pregnancy to treatment does not exceed 12 
months
High-risk 1. Antecedent pregnancy was a term pregnancy
2. Metastases in more than one site (outside the uterus)
3.  Metastases in one or more of the following organs: brain, liver, spleen, 
kidney, gastrointestinal tract
4. Failure of previous chemotherapy
5. Interval from end of index pregnancy to treatment exceeds 12 months
When one of the high-risk criteria is present, patients will be classified as high-risk and treated 
accordingly
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MAtEriAls AnD MEthoDs
Management protocols 
In the United Kingdom, all patients diagnosed with trophoblastic disease are regis-
tered centrally for hCG monitoring and follow-up. All patients registered with the 
Charing Cross GTD service gave consent for this to occur as part of the registration 
process. Since 2000 a division in low- and high-risk patients is made in accordance 
with the FIGO 2000 classification system for GTN. This determined the given treat-
ment, with low-risk patients being treated with methotrexate and high-risk patients 
being treated with multi-agent chemotherapy according to the EMA/CO regimen. In 
selected cases, actinomycin D is used when toxicity or resistance to methotrexate is 
present 1. In patients with detected pulmonary metastases intrathecal methotrexate 
as central nervous system (CNS) prophylaxis was additionally administered 26.
In the Netherlands patients with GTD are assigned to a low- or high-risk group, accord-
ing to the Dutch classification system for GTN. All patients with GTN are discussed in 
the Dutch Working party on Trophoblastic Disease and high-risk patients are treated 
in referral hospitals. Treatment for low- and high-risk patients respectively is fairly 
similar to the British regimen, mainly involving methotrexate for low-risk groups, with 
actinomycin D as an appropriate alternative and EMA/CO for high-risk groups 27. 
Patient selection 
The electronic database of the trophoblastic disease center at Charing Cross Hospital 
in London was screened to identify all patients with GTN diagnosed between January 
2003 and December 2012. All selected patients were retrospectively scored according 
to the Dutch Classification system for GTN and an overview of patients characteristics, 
treatment course and outcome was composed.  
One patient with PSTT was excluded because the classification and treatment for 
these patients is different. Furthermore, 15 patients were excluded when all or some 
criteria required for risk classification in either FIGO or Dutch classification were miss-
ing.
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statistics
A computerized database was developed, descriptive analyses was carried out with 
SPSS for windows 20.0. 
rEsults
Patient distribution 
A total of 828 patients were treated with chemotherapy for GTD in the UK between 
2003 and 2012, of which 813 patients had sufficient data available from the database 
for further analyses. Table 3 summarizes the distribution of patients according to the 
FIGO 2000 and Dutch classification system. In terms of risk classification both scoring 
systems were equivalent in 93.4% of cases. Discordant risk distribution when applying 
the FIGO classification system and Dutch classification system was seen in 53 patients 
(6.5%). In contrast with the FIGO 2000, fourteen patients (1.7%) would have been 
commenced on high risk treatment. Thirty-nine patients (4.8%) would have been low-
risk according to the Dutch classification and therefore treated with methotrexate 
instead of EMA/CO. 
All patients with widespread metastases and previous chemotherapeutic treatment 
were considered high-risk in both FIGO 2000 and Dutch classification system. One 
death associated with acute renal failure occurred as a result of complications during 
therapy after multi-agent treatment for widespread disease with metastases in both 
lungs and liver. The categorization for this patient by either classification system was 
high-risk. 
Patient characteristics and discrepancies 
Of the fourteen patients who would have been high-risk by the Dutch classification 
(but low by the FIGO 2000 criteria), one patient erroneously received EMA/CO as 
table 3. Distribution of patients in each subgroup according to FIGO 2000 and Dutch classification 
system.
low-risk FiGo high-risk FiGo total 
Low-risk Dutch system 711 (87.5%) 39 (4.8%) 750 (92.2%) 
High-risk Dutch system 14 (1.7%) 49 (6.0%) 63 (7.8%) 
Total 725 (89.2%) 88 (10.8%) 
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first line treatment. The other thirteen patients were commenced on single-agent 
treatment, with six achieving complete and sustained remission on single-agent and 
seven developing resistance to methotrexate and requiring subsequent EMA/CO. The 
antecedent pregnancy was a term gestation in 12 of these patients which made them 
high-risk in the Dutch classification system but their median FIGO score was 4 (range 
of 2 to 6). Patient characteristics and their decisive FIGO criteria per risk classification 
group are shown in Table 4.
Conversely 39 patients who would have been classified as low-risk by the Dutch classi-
fication were high-risk by the FIGO 2000 criteria. The majority of these patients (90%) 
had a serum hCG value preceding treatment of more than 100.000 IU/I  and tumor 
size of 5 cm, resulting in a combined score on the FIGO 2000 of 6 points. Moreover, 
the number of patients with an age of over 40 was substantially higher in this group, 
resulting in the additional 1 point on the FIGO 2000 for age in 62% of cases. Median 
FIGO score in this group was calculated at 7 (range of 7 to 12), whereas 94% of these 
patients had FIGO score of 7 or 8. In comparison, a median FIGO score of 12 was 
seen in the group considered high-risk by either classification system, with a FIGO 
score of 7 or 8 in 28% of cases. Complete sustained remission was achieved in all 
these patients with multi-agent chemotherapy with a median duration of treatment 
to normalization of 3 months (minimum 1, maximum 6 months). 
table 4. Patient characteristics and decisive FIGO criteria per risk classification group
FiGo low-risk FiGo high-hisk
Dutch low-risk
N=711
Dutch high-risk
N=14
Dutch low-risk
N=39
Dutch high-risk
N=49
Age >40 years  135 (19%) - 24 (62%) 8 (16%)
Widespread metastases a - - - 15 (37%)
Largest tumour >5cm 151 (22%) 1 (7%) 34 (87%) 22 (54%)
>8 metastases - - - 20 (49%)
Term pregnancy - 13 (87%) - 48 (98%)
Previous failed 
chemotherapy
- - - 5 (12%)
hCG pretreatment 
>100.000 IU/I
42 (6%) 13 (87%) 35 (90%) 17 (43%)
Median FIGO score 
(Min- Max)
3 (0-6) 4 (2-6) 7 (7-12) 12 (7-23)
a Kidney, Spleen, Gastro-intestinal, Liver and/or Brain
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DisCussion
In the present study a retrospective comparison of the FIGO 2000 and Dutch clas-
sification system for patients with GTN was performed. Both systems turned out to 
be widely equivalent with similar risk classification in up to 93.4% of cases, whereas 
the one death was only associated with high risk scores in both systems. Discordant 
risk scores when applying both systems were seen in 53 patients (6.5%), of which 14 
patients (1.7%) would have been considered high-risk according to the Dutch system, 
predominantly due to antecedent term pregnancy. Six of these patients achieved 
complete remission with MTX, whereas the remaining eight patients were fully sal-
vaged with second line EMA/CO. It is important to notice that even though numbers 
are small, overtreatment of these patients is of great clinical relevance. Combination 
therapy with EMA/CO as is recommended in case of high-risk disease is certainly toxic 
causing alopecia in nearly all, myelosuppression in most and neuropathy in many 
patients. Whilst these side-effects are all reversible, they are unpleasant and in the 
long-term the treatment advances the menopause date by about 3 years 5. In con-
trast, significant toxicity to the MTX/FA therapy used in the UK and the Netherlands 
in the form of severe stomatitis or serositis is very uncommon and there are no long 
term toxicities. The subsequent cancer risk for patients cured of GTN with modern 
chemotherapy regimen now appears similar to the general population, provided 
treatment duration is kept under 6 months 28. 
So what about the 39 (4.8%) patients considered as high-risk according to the FIGO 
2000 but low-risk if the Dutch system had been employed? This implies a potential 
for undertreatment when the Dutch classification system would have been used. 
Since this is a retrospective study, all of these individuals had already been treated 
with EMA/CO. Consequently, their possible response to single-agent MTX cannot 
be evaluated. The higher total FIGO scores for patients considered high-risk by both 
systems in comparison to the patients considered high-risk by FIGO but low-risk by 
the Dutch classification however illustrate existing differences in prognostic factors 
and thus possible differences in severity of disease. It is therefore conceivable that 
some patients in this group may have been responsive to MTX/FA treatment alone 
and that the more aggressive multi-agent regimen with its significant toxicity could 
have been avoided. A prospective designed trial rather than the present retrospective 
analysis would be needed to assess this particular patient group. Furthermore, a ret-
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rospective assignment of FIGO 2000 classification on the Dutch patient cohort would 
enable further insight in underlying differences. The treatment course of patients 
assigned to low-risk treatment in the Netherlands, when high-risk treatment would 
have been recommended according to the FIGO 2000 might demonstrate patients 
overtreated by this system. Unfortunately the individual prognostic scores on tumor 
size and number of metastases as requested in the FIGO 2000 were generally not 
available. Therefore retrospective evaluation of FIGO classification was not possible 
in this cohort. A comparison of  the proportion of misclassified patients according to 
both systems is therefore unavailable. 
Patients with a score of 6 or below in the FIGO system and term antecedent preg-
nancy may still present a gray zone between true low and high-risk disease. Patients 
can however be safely commenced on low-risk treatment with resistance being easily 
salvaged with EMA/CO without compromising mortality as this is only associated 
with higher FIGO scores 22,23,29. Serious prognostic factors such as extended metastatic 
disease and interval between antecedent pregnancy and subsequent GTN receive 
only relative weight in the FIGO 2000, where the Dutch system takes such factors as 
absolute decisive criteria. All patients with an interval of over 12 months or extended 
metastatic disease however were classified as high-risk using the FIGO 2000 system, 
implying that the involved tumor burden is probably simultaneously recognized 
by presence of other criteria.  An intrinsic correlation between term pregnancy, 
metastatic disease and high tumor load might also reveal whether term pregnancy is 
associated with higher resistance and mortality rates. In this regard, the risk criteria 
involved in the FIGO 2000 have previously been assessed in multivariate analyses, to 
identify the most significant predictors of treatment failure and poor prognosis. Most 
studies were however conducted in the eighties and early nineties, when treatment 
selection criteria, treatment regimens and outcome varied widely 30-33. Therefore, 
whilst these studies re-emphasized the problems of comparing worldwide data sets, 
it is unclear how valid the findings are  today.
In conclusion, the present study has highlighted the extensive overlap between both 
FIGO and Dutch scoring/staging systems even though items and relative value of 
items was quite distinct. It is not immediately obvious from the results of this study if 
one system is clearly superior to the other. The Dutch Classification seems to be sim-
pler and easier to apply in all situations. However in selected cases the Dutch system 
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actually leads to an overtreatment of patients. Unfortunately, since we did not have 
all the FIGO data recorded in the Dutch patients, it has not been possible for us to 
determine the potential rate of overtreatment with multi-agent chemotherapy in the 
FIGO 2000 scoring system. A degree of overtreatment with use of the FIGO system can 
however be presumed as well considering the present differences in total FIGO score 
for high-risk FIGO patients with either low-risk of high-risk Dutch classification. If the 
overtreatment rate was lower in the FIGO scoring system this would provide a strong 
case to replace the Dutch classification system. Pending this data, the only case to 
replace the Dutch system with the FIGO system is that of international unification to 
enable better cross correlation of therapy results between nations. In the meantime, 
we believe that further refinement of our risk classification systems through fresh 
univariate and multivariate analysis of the FIGO prognostic variables plus any new 
factors that appear promising would be useful.
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AbstrACt
background: Worldwide introduction of the FIGO 2000 scoring system has provided 
an effective means to stratify patients with gestational trophoblastic neoplasia 
(GTN) to single- or multi-agent chemotherapy. However, the system is quite elabo-
rate with an extensive set of risk factors. In this study, we re-evaluate all prognostic 
risk factors involved in the FIGO 2000 scoring system and examine if simplification 
is feasible.
Patients and methods: Between January 2003 and December 2012, 813 patients diag-
nosed with GTN were identified at the Trophoblastic Disease Center in London and 
scored using the FIGO 2000. Multivariable analysis and stepwise logistic regression 
were carried out to evaluate if the FIGO 2000 scoring system could be simplified. 
results: Of the eight FIGO risk factors only pre-treatment serum human chori-
onic gonadotropin (hCG) levels exceeding 10,000 IU/l (OR = 5.0; CI 2.5-10.4) and 
100,000 IU/l (OR = 14.3; CI 4.7-44.1), interval exceeding 7 months since anteced-
ent pregnancy (OR = 4.1; CI 1.0-16.2) and tumor size of over 5 cm (OR =  2.2; CI 
1.3-3.6) were identified as independently predictive for single-agent resistance. In 
addition, increased risk was apparent for antecedent term pregnancy (OR = 3.4; 
CI 0.9-12.7) and the presence of 5 or more metastases (OR = 3.5; CI 0.4-30.4), 
but patient numbers in these categories were relatively small. Stepwise logistic 
regression identified a simplified risk scoring model comprising age, pre-treatment 
serum hCG, number of metastases, antecedent pregnancy and interval but omit-
ting tumor size, previous failed chemotherapy and site of metastases. With this 
model only 1 of 725 patients was classified differently from the FIGO 2000 system.
Conclusion: Our simplified alternative using only five of the FIGO prognostic factors 
appears to be an accurate system for discriminating patients requiring single as 
opposed to multi-agent chemotherapy. Further work is urgently needed to validate 
these findings. 
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introDuCtion
Gestational trophoblastic disease (GTD) comprises a group of pregnancy related dis-
orders including the premalignant complete and partial hydatidiform moles through 
to the malignant invasive mole, choriocarcinoma, placental site trophoblastic tumor 
(PSTT), and epithelioid trophoblastic tumor (ETT) 1. The malignant counterparts are 
often collectively referred to as gestational trophoblastic neoplasia (GTN). Fortunately, 
with the introduction of effective chemotherapy, GTN has become highly curable with 
overall survival rates approaching 90% 1-4.
Cure for non-PSTT/ETT forms of GTN can often be achieved with single-agent che-
motherapy comprising either methotrexate (with or without folinic acid rescue) or 
actinomycin D. However some patients require multi-agent chemotherapy most com-
monly comprising etoposide, methotrexate, actinomycin D alternating weekly with 
cyclophosphamide and vincristine (EMA/CO) to achieve long-term remission 4. Over 
the years, several important predictors of unfavorable prognosis such as serum human 
chorionic gonadotropin (hCG) levels and site of metastases have been proposed 2,5,6 to 
stratify patients between single or multi-agent therapies. These factors have formed 
the basis of a number of different clinical scoring systems 5,7, used to distinguish GTN 
patients as either having a low or high-risk of developing resistance to single-agent 
chemotherapy.
To help facilitate comparison of datasets between international treatment centers, a 
renewed scoring system was introduced in 2000 8,9. The new FIGO 2000 risk scoring 
system was based on a combination of anatomic and pathophysiological features of 
the disease and was developed with the effort of a number of international societies 
including the International Society for the Study of Trophoblastic Diseases (ISSTD), 
the International Gynaecologic Cancer Society (IGCS) and International Fedaration of 
Gynaecology and Obstetrics (FIGO)9,10. 
The worldwide introduction of the FIGO 2000 has provided an opportunity to reach 
agreement on classification and subsequent treatment for patients with GTN. How-
ever, the system is quite elaborate and comprises an extensive set of risk factors, 
several of which relate to tumor bulk and may therefore not be independently prog-
nostic  2,6,11. A greater number of factors involved will likely result in an increased 
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variability in scoring and classification. Especially in a low-incidence disease like GTN, 
global unification is essential to optimize management. 
In this study, fifteen years following the introduction of FIGO 2000, we decided to re-
evaluate all prognostic factors involved in the FIGO 2000 scoring system to determine 
whether simplification of this system is feasible. 
MAtEriAls AnD MEthoDs
Patients 
All patients diagnosed with GTN between January 2003 and December 2012 were 
identified from the electronic database of the Trophoblastic Disease Center at Charing 
Cross Hospital in London. Patients with a histopathological diagnosis of PSTT or ETT 
were excluded, resulting in 813 GTN patients of which 725 were low-risk and 88 were 
high-risk by FIGO 2000 scoring. Uni- and multi-variable analyses were conducted for 
705 of 725 low-risk patients, since this was the total number of cases where their 
response to single-agent therapy was known. The remaining 20 patients had FIGO 
score 6 disease and either wanted high-risk treatment or were advised to start high-
risk treatment because of a very high pre-treatment serum hCG typically in excess of 
400,000 IU/L 12.
Management protocols 
Prior to treatment all patients were assigned to low or high-risk groups in accordance 
with the FIGO 2000 scoring system for GTN (Supplementary Table 1). Low-risk patients 
received single-agent methotrexate with folinic acid rescue (50 mg intramuscular 
MTX on days 1, 3, 5, and 7 and folinic acid 15 mg orally on days 2, 4, 6, and 8). In pa-
tients developing resistance or unmanageable toxicity, therapy was changed to either 
single-agent actinomycin D (ActD) or multi-agent chemotherapy comprising etopo-
side, methotrexate and actinomycin D alternating weekly with cyclophosphamide and 
vincristine (EMA/CO). The decision to use ActD as opposed to EMA/CO was based 
on the serum hCG level at the point of resistance. Patients with an hCG ≤ 300 IU/L 
received ActD whilst those > 300 IU/L were given EMA/CO as previously described 
13. ActD was given as 0.5 mg intravenously on days 1-5 every two weeks 13. Patients 
with disease resistant to ActD received EMA/CO chemotherapy subsequently. High-
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risk patients received multi-agent chemotherapy with EMA/CO as first-line therapy. 
In patients presenting with very advanced disease, induction low-dose etoposide 
and cisplatin was given prior to commencing either EMA/CO or EP/EMA (etoposide 
and cisplatin alternating weekly with etoposide, methotrexate and actinomycin D). 
Appropriate adaptation for occult or overt CNS disease was provided as previously 
described  14,15. Disease response and resistance to therapy was assessed by serum 
hCG measurements undertaken twice weekly until hCG was normal and then weekly 
until 6 weeks after completion of chemotherapy using the Charing Cross hCG radioim-
munoassay as previously described 4. 
statistical analysis
The predictive value of the prognostic factors for chemoresistance to MTX or ActD 
was assessed in low-risk patients using univariate and multivariable logistic regres-
sion. Thereafter, a backward stepwise (Wald) logistic regression was carried out for 
all patients to evaluate if simplification of the original FIGO system was feasible. To 
minimize the number of low-risk patients unnecessary subjected to the more aggres-
sive multi-agent chemotherapy with consequent toxicity, simplified models were only 
considered if at least 98% of patients had concordant FIGO classification. Guided by 
the previous results, a small set of modified FIGO models that best resembled clas-
sification of the original FIGO 2000 was constructed. Finally, with receiver operating 
characteristic (ROC) curves, the discriminating power of the alternative models in 
comparison to the original FIGO classification was evaluated. All statistical analyses 
were performed with SPSS for windows 22.0.
rEsults
Patient characteristics of the 813 patients with GTN are shown in Table 1. Twenty-eight 
percent of low-risk patients eventually needed salvage multi-agent chemotherapy 
after initial MTX/FA with or without subsequent ActD. One death associated with 
acute renal failure occurred as a result of complications during multi-agent therapy 
for widespread disease. 
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Table 2 shows the results of the univariate and multivariable analysis performed for 
low-risk patients treated with single-agent chemotherapy. Site of metastases and 
previous failed chemotherapy were not included in the analysis as all patients with 
widespread metastases or previous failed chemotherapy were classified as high-risk 
patients and therefore not treated with single-agent therapy. Tumor size, antecedent 
term pregnancy, interval and pre-treatment serum hCG were significant predictors for 
single-agent resistance in univariate analysis. In multivariable analysis, pre-treatment 
serum hCG levels exceeding 10,000 IU/L (OR = 5.0; CI 2.5-10.4) and 100,000 IU/L (OR 
= 14.3; CI 4.7-44.1), interval exceeding 7 months since antecedent pregnancy (OR = 
4.1; CI 1.0-16.2) and tumor size of over 5 cm (OR =  2.2; CI 1.3-3.6) were all identified 
as independent predictive factors for resistance to single-agent therapy. An increased 
table 1. Patient characteristics a
Patient characteristic low-risk patients (n=725) high-risk patients (n=88)
Mean (sd) min-max Mean (sd) min-max
Age (years) 32.2 (8.0) 14-56 34.7 (9.2) 15-62
Pre-treatment 10log  serum hCG (IU/l) 3.8 (1.1) 1-7 4.9 (1.1) 2-7
Interval (months) 1.8 (2.1) 0-35 10.5 (33.2) 0-242
Duration of treatment (months) b 1.9 (2.2) 0-15 2.8 (1.6) 0-10
FIGO score 2.7 (1.6) 0-6 10.3 (3.9) 7-23
Antecedent pregnancy Number Percentage Number Percentage
     Hydatidiform Mole 696 96.0 % 36 40.9 %
     Miscarriage 17 2.3 % 4 4.5 %
     Term 12 1.7 % 48 54.5 %
tumor size (cm) 
     <3cm 304 41.9 % 11 13.7 %
     3-5cm 240 33.1 % 13 16.3 %
     >5cm 152 21.0 % 56 70.0 %
site of metastases
     Vagina 4 0.6 % 4 5.0 %
     Lung 56 7.7 % 46 57.5 %
     Liver - - 6 7.5 %
     Brain - - 12 15.0 %
     Other - - 5 6.3 %
number of metastases
     None 662 91.4 % 23 28.7 %
     1-4 58 8.0 % 23 28.7 %
     5-8 4 0.6 % 7 8.8 %
     >8 - - 27 33.8 %
a For some patients scoring on one or more of the FIGO criteria was unavailable
b Duration of treatment is defined in months until normalization in serum hCG levels was reached
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risk was apparent for antecedent term pregnancy (OR = 3.4; CI 0.9-12.7) and the pres-
ence of 5 or more metastases (OR = 3.5; CI 0.4-30.4). However, numbers in these 
categories were relatively small. 
Using stepwise backwards (Wald) logistic regression, FIGO criteria lacking significant 
independent value were eliminated, identifying three simplified models. In these 
models 4 (model 2) or 5 (model 1 and 3) of the original 8 FIGO criteria were sufficient 
for identical risk classification in 99% of patients (Table 3). The discriminating power 
of these simplified FIGO scoring systems was compared to the original FIGO 2000 
table 2. Univariate and multivariable analysis of prognostic factors for single-agent resistance
Variable
rate of single-agent 
resistance (%)
odds ratio 
(95% Ci)a
odds ratio 
(95% Ci)a
univariate Multivariable
Age (years)
     <40 159/572 (27.8%)
     ≥40 34/133 (25.6%) 0.9 (0.6-1.4) 0.9 (0.6-1.5)
Antecedent pregnancy
     Hydatidiform Mole 183/677 (27.0%)
     Miscarriage 4/17 (23.5%) 0.8 (0.3-2.6) 0.6 (0.1-2.4)
     Term 6/11 (54.5%) 3.2 (1.0-10.7)b 3.4 (0.9-12.7)
interval (months)
     <4 179/617 (29.0%)
     4-6 9/73 (12.3%) 0.3 (0.2-0.7)b 1.1 (0.5-2.7)
     7-12 5/14 (35.7%) 1.4 (0.4-4.1) 4.1 (1.0-16.2)b
     >12 0/1 (0%) - -
Pre-treatment serum hCG (iu/l)
     <1000 19/167 (11.4%)
     1000-10.000 28/187 (15%) 1.4 (0.7-2.6) 1.6 (0.8-3.5)
     10.000-100.000 127/324 (39.2%) 5.0 (3.0-8.5)b 5.0 (2.5-10.4)b
     >100.000 19/27 (70.4%) 18.5 (7.1-48.0)b 14.3 (4.7-44.1)b
tumor size (cm)
     <3cm 55/302 (18.2%)
     3-5cm 61/232 (26.3%) 1.6 (1.1-2.4)b 0.9 (0.6-1.4)
     ≥5cm 71/142 (50.0%) 4.5 (2.9-7.0)b 2.2 (1.3-3.6)b
number of metastases
     None 172/644 (26.7%)
     1-4 19/56 (33.9%) 1.4 (0.8-2.5) 1.4 (0.7-2.6)
     5-8 2/4 (50.0%) 2.7 (0.4-19.6) 3.5 (0.4-30.4)
     >8 0/0 (0%) - -
a CI: Confidence Interval 
b p<0.05
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using ROC analysis. In model 1 and 2, six and seven patients respectively were classi-
fied differently. In model 3, with the elimination of tumor size, site of metastases and 
previous failed chemotherapy, classification for one patient changed from low-risk to 
high-risk. None of these patients had more than 4 metastases or metastases outside 
the lungs. Supplementary Table 2 shows the characteristics of all eight cases with a 
different risk classification when using one of the simplified alternatives in compari-
son to the FIGO 2000. 
DisCussion 
The FIGO 2000 comprises a weighted prognostic scoring system resulting in a cal-
culated total score and subsequent classification of GTN patients with low-risk and 
high-risk of resistance to single-agent chemotherapy. Most prognostic factors relate 
to tumor bulk, it is therefore questionable whether all these factors are required for 
adequate classification of patients 16. Furthermore, with the use of interrelated fac-
tors the actual weight for certain items could be overrepresented using FIGO 2000. 
With use of uni- and multivariable logistic regression, a smaller selection of risk fac-
tors could be identified as significant predictors for single-agent resistance 1-4. In con-
cordance with other studies, both tumor size and pre-treatment serum hCG emerge 
as important prognostic variables in our analysis 5,11. As all patients with GTN likely 
undergo imaging with pelvic ultrasound, tumor size can be derived quite easily in a 
non-invasive manner. In some cases, the volume of a trophoblastic tumor however 
may not represent the proportion of viable cells due to variations in the extent of 
necrosis and hemorrhage 17. Serum hCG is a disease-specific tumor marker, associ-
ated with burden of disease and is easily measured quantitatively. hCG levels of over 
10,000 IU/L and 100,000 IU/L in particular reflect strong relations to treatment failure 
in low-risk patients. As commercially available assays for quantification of serum hCG 
concentrations use different sets of antibodies and often a different standard, assay 
results strongly depend on the type of assay used. Although the effect is probably 
modest with high hCG levels, problems may occur with monitoring of response and 
follow-up in the lower range of hCG levels 1,17,18.
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While antecedent term pregnancy and interval since diagnosis have been associated 
with poor prognosis in univariate analyses, they however lose their significant prog-
nostic value in some multivariable analyses 2,6,19. For interval, the resulting hazard 
ratio appears non-linear and results likely depend on the chosen cutoff time. A sen-
sible cutoff point will probably be beyond 12 months since diagnosis, as suggested by 
Powles et al. 20. In our study only few patients had an interval exceeding 7 months, 
and likewise an increased risk of single-agent resistance was seen. In patients with 
antecedent term pregnancies, we observed an increased risk of single-agent resis-
tance, but even in this rather large cohort of patients, numbers in this subcategory 
remain small. Although choriocarcinoma could be considered a surrogate marker for 
antecedent term pregnancy, the latter term is preferred as histological confirmation 
is not always available. Problems with correct identification of the antecedent preg-
nancy and interval subsequently, can particularly occur when a patient has previously 
experienced an abortion without histological examination. 
The effect of advanced age in GTD incidence has been evaluated regularly 21-23. It’s 
possible effect on the development of GTN and survival however has been under 
debate2,5,6,11. In line with the majority of studies, age was not identified as an inde-
pendent prognostic factor in the present study. However, treatment often differs with 
advanced age, since hysterectomy is a reasonable treatment option when fertility 
preservation is not desired and a reduction of toxicity from chemotherapeutic regi-
mens may be profitable. Furthermore, considering all factors required for staging, age 
is probably one with the least possible uncertainty 17.
For both site of metastases and number of metastases, measurements are highly de-
pendent on the used imaging technology used. For practical purposes and uniformity, 
simple investigation tools such as X-ray provide adequate clinical guidance 17. Only 
few patients with a high number of metastases (5 or more) exist, possible implications 
on prognosis therefore remain unclear. Furthermore, there is wide consensus on the 
effects of widespread metastases on single-agent resistance and survival 2,5,6,11. In this 
cohort however, patients with widespread metastases were all characterized by a 
total FIGO score of over 10. Simultaneous presence of other prognostic factors has 
obviated the occurrence of misclassification in this group.
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We however have to keep in mind that the present FIGO score, whilst only designed 
for stratifying patients between low and high-risk treatments is also used to identify 
patients at greatest risk of early death within 4 weeks of commencing therapy and 
late death from multi-drug resistant disease. These ultra-high risk patients, present 
with widespread metastatic disease, reflected by a very high FIGO score (>12), are at 
significant risk for pulmonary, intra-peritoneal or intracranial hemorrhage and may 
benefit from low-dose induction chemotherapy. Furthermore, those with liver metas-
tases with or without brain metastases are at increased risk of late death 15. Removal 
of criteria that reflect these factors in a simplified system would hinder identification 
of these patient groups 14. Consequently, the new system will need to be carefully 
evaluated with sufficient patient numbers in the high- and ultra-high risk groups. 
Consensus exists on the concept of re-staging in case of relapse with full re-assess-
ment of spread of disease and previous chemotherapy response. Failure to respond 
to single-agent therapy already justifies the start of a different single-agent regimen 
or multi-agent therapy depending on hCG value. Confusion may however exist on the 
definition of failed chemotherapy. It would therefore be helpful to provide a clear 
definition on failed chemotherapy with the revised FIGO 2000 (i.e. rise of serum hCG 
after two chemotherapy cycles. 
It appears that only a small proportion of FIGO 2000 prognostic factors is needed to 
differentiate patients with low versus high-risk of single-agent resistance. This could 
lead to a relatively straightforward system with a small subset of easily retrievable fac-
tors, ideally reducing variability in scoring and improving agreement between centers. 
A simplified model with age, pre-treatment serum hCG levels, number of metastases, 
antecedent pregnancy and interval alone resulted in an identical risk classification as 
the original FIGO 2000 in all but 1 of the 194 low-risk patients that needed to switch 
to high-risk therapy. Tumor size, previous failed chemotherapy and site of metastases 
did not provide much added value. 
After fifteen years of experience with the worldwide accepted FIGO 2000, the present 
study provides a useful overview of its design and performance in a large nationwide 
cohort. Although the number of patients with resistance to single-agent therapy in the 
low-risk group made us inquisitive on possible improvements in the performance of 
FIGO 2000, exploration of possible improvement in classification is challenging when 
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only the prognostic factors currently employed in the FIGO 2000 are considered. Dop-
pler ultrasonography, used to measure uterine vascularity through pulsatility index 
has been suggested as an independent prognostic factor for resistance to single-agent 
chemotherapy 24. Further improvement by including novel variables such as Doppler 
pelvic ultrasonography should be considered. A renewed evaluation, preferably 
through international research collaboration would be needed to further validate 
these findings and refine FIGO 2000 into a straightforward classification system we 
could all embrace. 
Conclusion
The total FIGO score is determined by a summation of scores for eight prognostic fac-
tors. The majority of factors relate to tumor bulk and are not independently prognos-
tic for single-agent resistance. Our simplified alternative using only five of the FIGO 
prognostic factors remains an accurate system for discriminating patients requiring 
single as opposed to multi-agent chemotherapy. This simplified alternative would ide-
ally reduce variability in scoring and improve agreement between centers. However, 
further validation is required to ascertain how this system performs in distinguishing 
ultra-high risk and high-risk patients.
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supplementary table 1. FIGO 2000 Classification system GTN 
score 0 1 2 4
Age (years) <40 ≥40 - -
Antecedent pregnancy Mole Abortion Term -
Interval (months) <4 4-6 7-12 ≥13
Pre-treatment serum hCG (IU/l) <103 < 104 < 105 > 105 
Tumor size (cm) <3 3-4 ≥5 -
Site of metastases Lung Spleen, kidney Gastro-intestinal Liver, brain
Number of metastases - 1-4 5-8 >8
Previous failed chemotherapy - - Single drug Multi drug
A total score of 0-6 = low-risk; score ≥ 7 = high-risk
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Main aim of the present thesis was to further improve management of patients with 
GTN, through prediction of those patients requiring chemotherapeutic treatment and 
optimizing risk classification. With the introduction of effective chemotherapeutic 
treatment, GTN has become a highly curable disease with overall cure rates exceed-
ing 90% 1-3. To achieve this success, early detection and adequate treatment of GTN 
patients is essential, accompanied by accurate identification of those patients at risk 
of resistance to single-agent chemotherapy, since prompt treatment with more inten-
sive combination chemotherapy improves survival and shortens treatment duration. 
Combination chemotherapy with EMA/CO as is recommended in case of high-risk 
disease, however is toxic, causing alopecia, myelosuppression and neuropathy and 
should therefore be applied with caution 4. 
FolloW-uP AnD DiAGnosis oF Post-MolAr Gtn
For women diagnosed with a molar pregnancy the post-molar GTN risk and subsequent 
need for further chemotherapeutic management is approximately 0.5-1% for partial 
hydatidiform moles and 15-20% for complete hydatidiform moles 4-8. To enable early 
detection of patients with post-molar GTN, all patients with hydatidiform mole are 
subjected to recurrent hCG surveillance after molar evacuation 4. Serum hCG is a reli-
able marker for the detection of post-molar GTN, which is expressed by a plateaued or 
increased serum hCG concentration 9,10. Chapter 3 presents a regression corridor for 
uneventful both complete and partial hydatidiform moles, updating the normogram 
as presented by Yedema et al. in 1993 11. This new hCG normogram is applicable as a 
reference in the first-trimester ultrasound era and provides guidance during follow-up 
of patients with both complete and partial hydatidiform moles after evacuation. Since 
the configuration of a normogram is as dynamic as the patient group it affects, and 
the type of assay used, changes in future practice may require new adjustments over 
time and use of the normogram should be restricted to samples measured at the 
laboratory of the Dutch Central Registry for Hydatidiform moles. 
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PrEDiCtion oF Post-MolAr Gtn
It is unknown why after molar evacuation, some hydatidiform moles develop into 
post-molar GTN, while others go into spontaneous regression. Clinical characteris-
tics, such as advanced maternal age, large ovarian cysts and history of a prior mole 
have shown to be only weak predictors of post-molar GTN 1,12,13. Most studies have 
therefore focused on the tumor marker hCG. Although a normogram can support the 
detection of post-molar GTN, the tool is not suitable for early identification of patients 
at high-risk of post-molar GTN. To identify a means to predict post-molar GTN, some 
investigators have tried to predict post-molar GTN through differences in hCG regres-
sion patterns 11,14-17, others evaluated possible differences in hCG ratios obtained at 
different time intervals 18,19 or serum hCG levels taken at a given time point after 
evacuation 18,20. Although these studies emphasize the relevance of serum hCG as a 
reliable predictor of post-molar GTN, none of these findings were sufficiently accurate 
to guide individual management 11,15,16,18,19. In chapter 4 we present nomograms based 
on a single serum hCG value between 1 and 4 weeks after evacuation, to estimate 
the individual risk of post-molar GTN. All nomograms had good to excellent ability 
to distinguish between patients who will develop post-molar GTN and patients with 
uneventful hCG regression, reflected by a c-index value increasing from 0.83 in week 
1, to 0.95 in week 4. The development of these nomograms resulted in a simple and 
reliable tool to estimate the individualized risk of post-molar GTN, based on a single 
serum hCG measurement. With the use of this tool, clinicians can provide proper 
counseling of all complete hydatidiform mole patients and identify patients at high-
risk of post-molar GTN. Validation in an independent and preferably larger dataset is 
needed to further strengthen our findings. Trophoblastic centers worldwide however 
use different hCG assays with varying specificity for particular subtypes of hCG. An 
external validation of the prediction tool as presented in chapter 4, on a different 
patient group, but measured with the same hCG assay is therefore not feasible. An 
independent cohort with serum hCG values obtained using a different hCG assay  can 
however be used to validate the approach of predicting post-molar GTN with the use 
of nomograms. In the United Kingdom, a non-commercial in-house hCG RIA assay, 
using a rabbit polyclonal antibodies is used for monitoring all GTD patients. With the 
use of this independent and considerably large dataset, one could validate whether 
the approach described in chapter 4, can be extended to a different assay. 
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uniForMitY in ClAssiFiCAtion
The use of a clinical scoring system to classify GTN patients with recognized prognos-
tic criteria was first described by Bashawe in 1976 21. He investigated 317 patients 
with GTN and identified ten factors associated with response to chemotherapy. 
Patients with GTN can subsequently be classified with low-risk or high-risk disease 
and treated accordingly. The derived weighted prognostic scoring system, formed the 
basis for many other classification systems such as the World Health Organization 
(WHO) classification system and more recently the FIGO 2000 22-24. Unlike the FIGO 
2000 system, the Dutch classification system uses a small subset of absolute criteria 
to stratify patients into low or high-risk for developing single-agent resistance, includ-
ing antecedent term pregnancy and previous failed chemotherapy 22,25. Although this 
system provides relatively straightforward classification, it hampers the comparison 
of Dutch management results with those obtained worldwide 25. Chapter 5 described 
a retrospective comparison of the FIGO 2000 and the Dutch classification systems for 
patients with GTN. Both systems turned out to be widely equivalent with similar risk 
classification in up to 93.4% of cases, even though items and scoring of these items 
were quite different. Discordant risk distribution was predominantly seen in patients 
with antecedent term pregnancy. In the Netherlands term pregnancy in itself is con-
sidered an indicator for poor prognosis, whereas the FIGO 2000 system only allocates 
a relative weight to this criterion. Although a lower cure rate after term pregnancy 
has been reported in several studies, an intrinsic correlation between term pregnancy 
and other factors for poor prognosis such as the presence of widespread metastases, 
a prolonged interval between diagnosis and antecedent pregnancy and the involved 
tumor burden is likely present. The actual presence of these other prognostic factors 
in patients with antecedent term pregnancy may therefore be equally essential 26-30. 
To realize comparison of therapy results with other nations, we propose replacement 
in the Netherlands of the Dutch classification system with the FIGO 2000 system. Con-
sidering the possibilities for simplification and improvement as suggested in chapter 
6, replacement of the Dutch classification system should ideally involve a refined 
edition of the FIGO 2000 scoring system.
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risK ClAssiFiCAtion: is lEss rEAllY MorE?
The comparison of the Dutch classification system with the FIGO 2000 system in chap-
ter 5 has provided insight in the extensive overlap in classification of both systems. 
The relative abundance of criteria in the FIGO 2000 however made us inquisitive on 
the possibilities to simplify the system without compromising outcome. Many risk 
factors involved in the FIGO 2000 scoring system relate to tumor bulk and may not be 
independently prognostic 26,28,31,32. Chapter 6 presents a re-evaluation of all prognostic 
factors involved in the FIGO 2000 system and an examination whether simplification 
is feasible. 
With the use of stepwise backwards (Wald) logistic regression a simplified risk scoring 
model was identified comprising the factors age, pre-treatment serum hCG, number 
of metastases, antecedent pregnancy and interval, thus omitting tumor size, previ-
ously failed chemotherapy and site of metastases. A reduction of the number of 
factors involved in the FIGO system will likely result in reduced variability in scoring 
and classification. Especially in a low incidence disease like GTN, unification between 
centers is essential to optimize management. 
Using simplified model 3 as presented in chapter 6, identical classification in all but 
one patient was obtained when compared to FIGO 2000. Would elimination of the 
factors tumor size, previously failed chemotherapy and widespread metastases truly 
support agreement in classification when used in daily practice? Failure to respond 
to single-agent therapy always justifies the start of either a different single-agent 
regimen or a multi-agent regimen depending on serum hCG value. Confusion may 
however exist on the definition of previous failure of chemotherapy and scoring as 
such in the FIGO 2000 system. Would a single shot of MTX administered at an initial 
suspicion of extra-uterine gravidity imply previous failure of chemotherapy for GTN? 
In addition, although tumor size can be derived quite easily in a noninvasive man-
ner, the volume of a trophoblastic tumor may not represent the proportion of viable 
cells in a tumor mass due to variations in the extent of necrosis and hemorrhage 33. 
Trophoblastic tumor masses have a slow radiologic resolution, particularly with bigger 
masses. In several instances, opacities took more than a year to fully dissolve after 
the end of chemotherapy. In follow-up and restaging this should therefore be taken 
explicitly into consideration 21. In uni- and multivariable analysis, we showed tumor 
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size to be a significant predictor of the need for salvage therapy in the low-risk group, 
which is in line with other studies 32. In our study, all of these patients were fully 
salvaged. In addition, a tumor size of over 5 cm was also commonly seen in the single-
agent responsive group. Proposing a prominent role for tumor size in the classification 
system by allotting additional points is therefore not the answer. Finally, considering 
the elimination of widespread metastases as a separate criterion in FIGO 2000, it is 
important to realize that the present FIGO score, whilst only designed for stratifying 
GTN patients to low and high-risk treatment, does give us an indication of the patient 
group at risk of early death after initiating chemotherapy, or late death from multi-
drug resistant disease 29,34,35. Patients with widespread disease, commonly reflected 
by a very high FIGO score (>12), are at significant risk of pulmonary, intra-peritoneal 
or intracranial hemorrhage and may benefit from low-dose induction chemotherapy. 
Especially liver and brain involvement reduces the long-term survival substantially 
36-38. Removal of site of metastases as a risk criterion would hinder identification of 
this patient group 39. Consequently, a new system will need to be carefully evaluated 
with sufficient patient numbers in the high- and ultra-high-risk groups. 
Altogether, the elimination of tumor size and previously failed chemotherapy would 
simplify the current classification system and could subsequently reduce variability in 
scoring and improve agreement. Considering the number of patients with resistance 
to single-agent chemotherapy in the low-risk group, the possibility to refine the FIGO 
classification system should additionally be evaluated. Although improvement ap-
pears challenging when only prognostic factors currently applied in the FIGO 2000 
are considered, variables such as Doppler ultrasonography, used to measure uterine 
vascularity through pulsatility index have been suggested as an independent prognos-
tic factor for resistance to single-agent chemotherapy 40. If introduction of Doppler 
ultrasonography with simultaneous simplification of the model would result in a 
decline of non-responders in the low-risk group without compromising single-agent 
responders by erroneously assigning them to high-risk therapy in an independent 
dataset, a simple but refined classification could result. 
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rECoMMEnDAtions in thE MAnAGEMEnt oF Gtn
Consensus in terminology and diagnostic criteria
To acquire consensus in the management of GTN, standardizing risk classification is 
ideally accompanied by standardized terminology and diagnosis. GTN differs from 
most other solid tumors, for which histological confirmation is recommended 10. The 
condition has subsequently received many denominators based on pathology, labora-
tory results and clinical behavior (e.g. gestational trophoblastic tumor, persistent tro-
phoblastic disease, malignant GTD) 33.  To avoid confusion, it is recommended to use 
one general term for all patients with abnormal gestational trophoblastic proliferation 
requiring treatment for a potential or proven malignancy. At the FIGO 2000 meeting in 
2003, the term gestational trophoblastic neoplasia (GTN) was therefore recommend-
ed to replace all other terminology 41. Though this entity gradually reaches universal 
acceptance, differences in the diagnostic criteria for GTN still exist. The International 
Federation of Obstetrics and Gynecology (FIGO) defines GTN as: 1) plateau in hCG 
concentration in 4 consecutive blood samples over a period of 3 weeks and/or, 2) 
a rise in hCG concentration for 3 consecutive samples over a period of 2 weeks 42. 
Some will include persistence of detectable hCG concentrations 6 months after evacu-
ation as an additional criterion, while others include the pathological confirmation of 
choriocarcinoma as an absolute criterion 4,33,43. Furthermore the actual cut-off values 
of hCG rise or plateau is still left to the discretion of the individual physician. Only 
by unifying the definition of diagnosis, meaningful comparison of management out-
come is feasible. The following unequivocal criteria for GTN are therefore proposed, 
predominantly based on recommendations of the FIGO 2000 meeting: 1) a plateau in 
hCG concentration for 4 consecutive blood samples over a period of 3 weeks (defined 
as equivalent values not exceeding an overall 10% rise or decline over this 3 week 
period), 2) two consecutive rises in hCG concentration of 10% or more for at least 
2 weeks, and 3) histopathological diagnosis of choriocarcinoma, as in this case the 
disease is unlikely to spontaneously disappear 6. An elevated but falling hCG 6 months 
after evacuation should no longer be used as an absolute criterion, because with 
continuous surveillance, spontaneous serum hCG normalization eventually occurred 
in all of these patients 44,45. 
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Consensus in the use of investigative tools
When the diagnosis of GTN is established, usually through hCG follow-up, a workup 
with diagnosis of metastases and an evaluation for the presence of risk factors should 
be performed 43,46. Although it is tempting to use more sophisticated technology such 
as computed tomography (CT) scans or magnetic resonance imaging (MRI) providing 
much better resolution than conventional imaging, chest X-ray is appropriate for the 
detection of lung metastases, since the presence of micro metastases does not influ-
ence management and outcome 47,48. Only when lesions are detected on a chest X-ray, 
CT-thorax/abdomen and MRI of the brain are indicated to evaluate the presence of 
widespread disease, which significantly alters management and prognosis 6,44. 
Regarding follow-up, a reliable serum hCG assay is essential for the management of 
patients with GTD. hCG is a heterogeneous molecule, produced by trophoblastic tis-
sue during pregnancy 49. hCG comprises an α-subunit (shared with other glycoprotein 
hormones including luteinizing hormone, follicle-stimulating hormone and thyroid-
stimulating hormone) and a β-subunit that confers specificity 50. Besides intact hCG, 
an assay used to monitor hCG values in patients with gestational trophoblastic disease 
should therefore target the β-subunit 51. In the first trimester of healthy pregnancies, 
hCG is predominantly present in the native form. In trophoblastic disease, hCG can 
exist in a number of fragments. There are currently many commercial sandwich-type 
assays available for normal pregnancy. Commercial assays variously detect all forms 
of hCG, resulting in different results 52,53. In the Netherlands, an in-house developed 
radioimmunoassay (RIA) designed to specifically detect both intact hCG and free 
β-subunit is used for all measurements in sera sent to the Dutch Central Registry 
for Hydatidiform Moles since 1977 11. Based on measurements performed with this 
specific immunoassay, several tools have been developed to guide follow-up and 
management of GTD patients, including the hCG regression curve discussed in chap-
ter 3 of this thesis and the prediction tool presented in chapter 4 of this thesis. Since 
specificity for the different forms of hCG differs between hCG assays, results from 
these studies will only apply to measurements performed at laboratory of the Dutch 
Central Registry. Although the registry provides nationwide hCG measurement service 
for gynecologists, standard use of this assay is still not reached. Centralization of care 
in the Netherlands may induce standard use of this specific assay and thus enable 
uniformity in hCG measurement and subsequent management nationwide. 
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international registration and collaboration 
The Dutch Central Registry for Hydatidiform Moles was established in 1977 and re-
sides at the Radboud University Medical Center in the Netherlands. This voluntary 
registry mainly serves as an epidemiological database for all patients with gestational 
trophoblastic disease. Patients with GTN are quarterly discussed in the Dutch Working 
party on Trophoblastic Disease. In the United Kingdom, clinicians are obliged to regis-
ter all patients diagnosed with trophoblastic disease centrally for hCG monitoring and 
follow-up since 1973. Only two hospitals in the UK are designated to treat patients 
with GTD. Today, the electronic database holds records of over 35,000 women with 
GTD and provides excellent data for research and audit 54,55. Following these examples, 
Belgium, France and other European countries have set up a national registration 
system to guide physicians and improve the management of patients with GTD 56,57. 
After wide agreement that a European network for clinicians and researchers working 
in the field of GTD would lead to an improvement in knowledge and management 
of patients with GTD, the European Organization for Treatment of Trophoblastic 
Diseases (EOTTD) was established in 2009. Facilitated by this organization, interna-
tional guidelines have been formulated 6, centralized management of patients was 
encouraged and collaboration in research was stimulated 58. Institution of an online 
database for GTD patients registered in all participating countries of the EOTTD would 
however truly take international research collaboration to a higher level. Especially in 
case of GTN, international multi-center collaborations are needed to study sufficient 
numbers of patients.
FuturE PErsPECtiVE
The present thesis discusses simplification of the FIGO 2000 system through elimina-
tion of tumor size and previously failed chemotherapy as prognostic criteria (chapter 
6). Ideally this should be accompanied by simultaneous improvement of the FIGO 
2000 system, as a reduction of misclassified low-risk patients would result in reduced 
treatment duration and earlier permission for a renewed pregnancy. Doppler ul-
trasonography has been suggested as an independent predictor of MTX resistance 
in patients with a FIGO score of 5-6  59. To explore the prognostic value of Doppler 
ultrasonography for all low-risk GTN patients, this factor should be added to the 
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multivariable analyses in our dataset. If a reduced misclassification-rate could indeed 
be realized by adding this factor, the next step would be to consider all independent 
prognostic criteria involved in the FIGO 2000 and Doppler ultrasonography prospec-
tively. Chapter 5 discussed the milder characteristics of a number of patients with a 
FIGO 2000 score of 7, predominantly with tumor size exceeding 5 cm, pretreatment 
serum hCG exceeding 100,000 IU/l and age of over 40 years, but absence of serious 
prognostic factors such as widespread metastases. It is conceivable that this patient 
group presents a gray zone and some of these patients may have been responsive 
to single-agent chemotherapy alone. An evaluation of their response to single-agent 
chemotherapy may be considered to see if the more aggressive multi-agent regimen 
with significant toxicity could be avoided. Through international research collabora-
tion, the possible response to single-agent chemotherapy can be evaluated for all 
patients with a FIGO score of 0-8 and absence of widespread metastatic disease. 
Single-agent chemotherapy as first-line therapy appears to be safe in this particular 
patient group. In Denmark, methotrexate is considered first-line treatment in all pa-
tients with non-PSTT/ETT GTN, with ActD or multi-agent chemotherapy as second- or 
third-line treatment of choice 60. Patients with widespread disease and/or ultra-high 
risk disease should be commenced on multi-agent chemotherapy to ensure optimal 
chances of survival. In this new cohort of patients, a new multivariable logistic regres-
sion can subsequently be conducted, including all prognostic criteria involved in the 
simplified scoring system and Doppler ultrasonography measurements to identify in-
dependent risk factors for single-agent chemotherapy resistance. Besides a validation 
of the study results as presented in chapter 6, this will provide additional information 
regarding the possible response to single-agent chemotherapy in patients with a FIGO 
score of 7 or 8. All factors with independent prognostic value can be implemented in 
a renewed and further simplified system of factors, while eventual weighting of all 
individual factors can be derived from the regression coefficients in multivariable lo-
gistic regression analysis. Alongside further consensus and unification worldwide, this 
renewed classification system would ideally result in a reduced misclassification-rate. 
Some additional steps should be made before implementation of such a system is 
completed. First of all, one should consider the threshold for low versus high-risk 
disease, ensuring adequate recognition of non-responders without considerable 
compromise on single-agent responders by erroneously assigning them to high-risk 
therapy. The Receiver Operating Characteristic (ROC) curve plotting the sensitivity 
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against the 1-specificity of this renewed system, will be helpful in decision of the 
optimal cutoff score for low versus high-risk disease. And finally, we will need to re-
evaluate the threshold for ultra-high-risk patients as these patients may benefit from 
low-dose induction chemotherapy. 
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suMMArY 
Gestational trophoblastic disease (GTD) comprises a group of uncommon conditions 
associated with abnormal pregnancy. Histologically it includes the premalignant 
conditions of complete and partial hydatidiform mole, as well as the malignant coun-
terparts choriocarcinoma, placental site trophoblastic tumor and epithelioid tropho-
blastic tumor. The malignant counterparts are collectively referred to as gestational 
trophoblastic neoplasia (GTN). 
Chapter 1 reviews the most recent insights in epidemiology, diagnosis, treatment mo-
dalities and prognosis of patients with GTN, serving as an introduction to the studies 
performed and described in this thesis. 
In chapter 2 the trends in incidence of gestational trophoblastic disease in the Nether-
lands are determined using population-based data from PALGA, a national pathology 
database containing all histopathological records in the Netherlands. In the 20-year 
period between 1994 and 2013, 6341 cases of GTD were registered, representing an 
overall incidence rate of 1.66 per 1000 deliveries per year. An initial rise in incidence 
rate over the first ten years (increase per year 0.075, 95% CI 0.040-0.109 per 1000 
deliveries per year) was followed by a stabilization from 2004 to 2013 (increase per 
year 0.011, 95% CI -0.017-0.040 per 1000 deliveries per year). From 2009 onwards a 
comparable incidence was reached for both complete and partial hydatidiform moles 
(incidence rates of 0.68 and 0.64 per 1000 deliveries respectively) and unspecified 
hydatidiform mole diagnosis declined significantly (from 0.14 per 1000 deliveries in 
2003 to 0.03 per 1000 deliveries in 2013). The introduction of ancillary techniques 
such as p57kip2 and ploidy analysis have likely improved the accuracy of diagnosis and 
therefore the actual estimates of GTD cases as registered by the Dutch pathological 
database (PALGA). As pathological confirmation is currently the norm and advanced 
pathological techniques are now widely available, reliable steady incidence rates may 
now have been reached. 
The glycoprotein hormone human chorionic gonadotropin (hCG), produced by 
trophoblastic tissue, is a sensitive marker for monitoring trophoblastic activity in 
pregnancy and gestational trophoblastic disease. hCG surveillance after evacuation of 
a hydatidiform mole is essential in the management of GTD. In chapter 3 a new serum 
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hCG normogram is proposed, based on 639 patients with both uneventful complete or 
partial hydatidiform moles between 1990 and 2014. So far, Dutch clinicians relied on a 
normogram as presented by Yedema in 1993, based on a historical cohort of patients 
with uneventful regression after a complete hydatidiform moles alone. Compared to 
the historical cohort of Yedema et al., lower pre-evacuation and follow-up serum hCG 
concentrations were observed in our study cohort. Moreover, a small but significant 
divergence in hCG regression between complete and partial hydatidiform moles was 
seen (median hCG normalization time of seven weeks and six weeks respectively, 
p<0.001). As actual differences in regression only encompassed days, we proposed 
the use of a combined normogram for both complete and partial hydatidiform moles 
to promote clarity and unity in daily practice. The normogram replaces the regression 
corridor as presented by Yedema et al. and is applicable as a reference guideline for 
follow-up after evacuation of a hydatidiform mole in the first-trimester ultrasound 
era. 
Chapter 4 presents a nomogram for patients with hydatidiform moles, to enable early 
identification of patients at high-risk of post-molar GTN. Between 1990 and 2014 
serum hCG values, taken 1 to 4 weeks after evacuation were retrospectively evaluated 
for patients with uneventful serum hCG regression and patients with post-molar GTN. 
Logistic regression was used to generate nomograms for every week after evacuation, 
based on serum hCG measurements at that given week. The discriminative ability of 
the prognostic models, or the ability to distinguish women with low-risk of post-molar 
GTN from women with high-risk of post-molar GTN, was expressed by means of the 
concordance index (c-index). For a binary outcome, c is identical to the area under 
the receiver-operating characteristics (ROC) curve (AUC). With a c-index value ranging 
from 0.83 in week 1, to 0.95 in week 4, all nomograms had good to excellent ability 
to distinguish women with low-risk of post-molar GTN from women with high-risk 
of post-molar GTN. The development of these nomograms resulted in a simple and 
reliable tool to estimate the individualized risk of post-molar GTN, based on a single 
serum hCG measurement. Early start of chemotherapeutic treatment may be benefi-
cial in patients at high-risk of post-molar GTN, especially in case of poor compliance 
to follow-up. 
The possible benefits of hysterectomy on treatment duration and treatment toxicity 
for patients with GTN are explored in Chapter 5. Although chemotherapy is gener-
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ally the treatment of choice in patients with GTN, hysterectomy is still considered 
in selected cases. All patients diagnosed with GTN and treated with a hysterectomy 
between 1977 and 2012, were identified from the Dutch Central Registry for Hyda-
tidiform Moles and records of the Dutch Working party of Trophoblastic Disease. One 
hundred and nine patients (16.5% of all registered patients with GTN) underwent hys-
terectomy as part of their management for GTN. The majority of these patients was 
classified as low-risk disease (74.3%), post-molar GTN (73.5%) and disease confined 
to the uterus (65.1%). After hysterectomy alone, complete remission was achieved 
in 66.2% of patients with localized disease and in 15.8% of patients with metastatic 
disease. For patients with localized disease, treated with primary hysterectomy, treat-
ment duration was significantly shorter (mean 3.2 weeks and 8.0 weeks respectively, 
p=0.01) with lower number of administered chemotherapy courses (mean 1.5 and 
5.8 respectively, p<0.01) than patients in a matched control group. We therefore 
concluded that hysterectomy can still be considered an effective treatment option to 
either reduce or eliminate tumor bulk in selected cases. Primary hysterectomy should 
be considered mainly for patients over forty years of age with localized disease and 
no desire to preserve fertility, whereas patients with chemotherapy-resistant disease 
may benefit from additional hysterectomy, especially when disease is localized. For 
patients with widespread metastatic disease, the benefit of hysterectomy generally 
lies in the removal of chemotherapy-resistant tumor bulk to improve survival. 
Once the diagnosis of GTN has been made, different prognostic classification systems 
can be used to stratify patients with GTN to single- of multi-agent chemotherapy. To 
validate and improve management of GTN between nations, it is essential to reach 
consensus on the used classification system and subsequent management protocols. 
Chapter 6 describes a comparison between the Dutch classification system and the 
internationally used FIGO 2000 for patients with GTN. All patients diagnosed with 
GTN between 2003 and 2012 at the Trophoblastic Center in London and originally 
classified according to the FIGO 2000, were retrospectively scored according to the 
Dutch classification system. Risk classification with both systems was equivalent in 
93.4% of cases, even though items and scoring were quite distinct. The Dutch system 
seems to be more simple and easier to apply, a degree of overtreatment can however 
be presumed with the use of either system. Considering the extensive overlap in risk 
factors involved in FIGO 2000, we concluded that further refinement of FIGO 2000 
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through a renewed univariate and multivariable analysis of the FIGO prognostic crite-
ria would be useful. 
In chapter 7 we re-evaluate all prognostic criteria involved in the FIGO 2000 classifica-
tion system and examine whether simplification of this system is feasible. A total of 
813 patients diagnosed with GTN between 2003 and 2012 at the Trophoblastic Center 
in London and scored using FIGO 2000 were identified. Multivariable analysis and 
stepwise logistic regression were carried out to evaluate whether FIGO 2000 could 
be simplified. Of the eight FIGO risk factors only pre-treatment serum hCG levels 
exceeding 10,000 IU/l (OR = 5.0; CI 2.5-10.4) and 100,000 IU/l (OR = 14.3; CI 4.7-
44.1), interval exceeding 7 months since antecedent pregnancy (OR = 4.1; CI 1.0-16.2) 
and tumor size of over 5 cm (OR =  2.2; CI 1.3-3.6) were identified as independent 
predictive factors for single-agent resistance. Stepwise logistic regression identified 
a simplified risk scoring model comprising age, pre-treatment serum hCG, number 
of metastases, antecedent pregnancy and interval, thus omitting tumor size, previ-
ous failed chemotherapy and site of metastases. With this model only 1 out of 725 
patients was classified different from the FIGO 2000 system. Our simplified alternative 
using only five of the FIGO prognostic factors appears to be an accurate system for 
discriminating patients requiring single as opposed to multi-agent chemotherapy.
Chapter 8 summarizes and discusses the main findings of the present thesis. We 
especially stressed the need for consensus in terminology, diagnosis and treatment. 
Since multi-center and international collaboration are the only means to study suf-
ficient number of patients in a low-incidence disease like GTN, variability in definition, 
diagnosis and treatment should be kept to an absolute minimum. To realize cross 
comparison of treatment results with other nations we propose replacement of the 
Dutch risk classification system with FIGO 2000. Considering the possibilities for sim-
plification and improvement of FIGO, the replacement should ideally involve a refined 
edition. Considerations for further exploration of the refined FIGO with a proposal for 
future research is discussed. 
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sAMEnVAttinG
De term trofoblastziekten (gestational trophoblastic disease, GTD) omvat een groep 
zeldzame aandoeningen die geassocieerd is met een abnormale zwangerschap. 
Histologisch gezien, behoren hiertoe zowel de premaligne aandoeningen complete 
en partiële mola, als de maligne tegenhangers choriocarcinoom, placental site trop-
hoblastic tumor en epithelioid trophoblastic tumor. Deze maligne aandoeningen 
worden gezamenlijk ook trofoblasttumor, of internationaal gestational trophoblastic 
neoplasia (GTN) genoemd. 
hoofdstuk 1 beschrijft de meest recente inzichten in epidemiologie, diagnose, be-
handeling en prognose van patiënten met GTN, als introductie op de studies die zijn 
uitgevoerd en beschreven in dit proefschrift. 
In hoofdstuk 2 worden de trends in incidentie van trofoblastziekten (GTD) in Neder-
land beschreven, met behulp van op populatie gebaseerde data die werd verkregen 
uit PALGA, een landelijke databank met alle pathologie-uitslagen in Nederland. In een 
periode van 20 jaar, tussen 1994 en 2013, werden 6341 gevallen van GTD geregis-
treerd, wat resulteert in een incidentie van 1.66 per 1000 bevallingen per jaar. Een ini-
tiële toename in incidentie in de eerste tien jaar (toename per jaar van 0.075, 95% CI 
0.040-0.109 per 1000 bevallingen per jaar) werd daarbij gevolgd door een stabilisatie 
van 2004 tot 2013 (toename per jaar 0.011, 95% CI -0.017-0.040 per 1000 bevallingen 
per jaar). Vanaf 2009 waren de incidentie voor complete en partiële hydatidiforme 
mola hydatidosa vergelijkbaar (incidentie van respectievelijk 0.68 en 0.64 per 1000 
bevallingen) en was sprake van een significante afname in ongespecificeerde mola 
hydatidosa  (van 0.14 per 1000 bevallingen in 2003 naar 0.03 per 1000 bevallingen 
in 2013). De introductie van aanvullende technieken zoals p57kip2 en ploidie-analyse 
hebben waarschijnlijk bijgedragen aan de toegenomen accuraatheid in diagnose en 
daarmee de daadwerkelijke bepaling van GTD gevallen zoals geregistreerd door de 
Nederlandse pathologie database (PALGA). Aangezien pathologische bevestiging van 
de diagnose momenteel de norm is en aanvullende pathologische technieken ruim-
schoots beschikbaar zijn, is hiermee mogelijk een betrouwbaar en stabiel incidentie 
cijfer bereikt.  
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Het glycoproteïne hormone human chorionic gonadotropin (hCG), geproduceerd 
door trofoblastweefsel, is een sensitieve merkstof om trofoblastactiviteit in zowel 
gezonde zwangerschappen als GTD te vervolgen. hCG controle na evacuatie van een 
mola hydatidosa is essentieel in de behandeling van GTD. In hoofdstuk 3 wordt een 
nieuw serum hCG normogram voorgelegd, gebaseerd op 639 patiënten met spontane 
normalisatie van hCG concentraties na een complete of partiële mola hydatidosa 
tussen 1990 en 2014. Tot op heden waren Nederlandse clinici voor follow-up en 
diagnose afhankelijk van een normogram zoals gepresenteerd door Yedema in 1993. 
Dit normogram is gebaseerd op een historisch cohort van alleen complete mola hy-
datidosa patiënten met spontane normalisatie in hCG concentratie. In vergelijking tot 
het historische cohort van Yedema, zagen wij lagere pre-evacuatie en follow-up serum 
hCG concentraties in onze studie groep. Daarbij bleek sprake van een klein maar signi-
ficant verschil in hCG regressie tussen complete en partiële mola hydatidosa (mediane 
hCG normalisatie tijd van respectievelijk zeven en zes weken, p<0.001). Aangezien 
de daadwerkelijke verschillen in regressie uiteindelijk slechts enkele dagen betreffen, 
adviseren wij het gebruik van een gecombineerd normogram voor zowel complete als 
partiële mola hydatidosa, ter bevordering van een heldere en uniforme werkwijze in 
de dagelijkse praktijk. Dit normogram zal de regressie corridor zoals gepresenteerd 
door Yedema vervangen en is ook in de huidige praktijk waar routine eerste-trimester 
echoscopie de norm is, toepasbaar als referentiekader voor follow-up van patiënten 
met mola hydatidosa na curettage. 
hoofdstuk 4 presenteert een nomogram om vroege identificatie van patiënten met 
een hoog risico op post-mola GTN mogelijk te maken. Hiertoe werd een retrospec-
tieve analyse verricht van alle serum hCG waarden, afgenomen tussen 1 en 4 weken 
na evacuatie bij patiënten met spontane regressie en patiënten met post-mola GTN. 
Door middel van logistische regressie analyse werd vervolgens, gebaseerd op een 
enkele serum hCG meting in die desbetreffende week een nomogram gegenereerd. 
Het onderscheidend vermogen van de prognostische modellen, ofwel de mogelijk-
heid om vrouwen met laag-risico op post-mola GTN van vrouwen met hoog-risico op 
post-mola GTN te onderscheiden, werd uitgedrukt in de concordance index (c-index). 
Voor binaire uitkomsten, is c identiek aan de oppervlakte onder de receiver-operating 
characteristics (ROC) curve (AUC). Met een c-index waarde variërend van 0.83 in week 
1, tot 0.95 in week 4, bleken alle nomogrammen een uitstekend vermogen te hebben 
om vrouwen met laag-risico op post-mola GTN van vrouwen met hoog-risico op post-
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mola GTN te onderscheiden. De ontwikkeling van deze nomogrammen resulteerden 
dan ook in een eenvoudige, maar betrouwbare tool om het individuele risico op 
post-mola GTN, gebaseerd op een enkele hCG meting, in te schatten. Vroege start 
van chemotherapeutische behandeling kan van meerwaarde zijn bij patiënten met 
een hoog-risico op post-mola GTN, vooral als sprake is van matige compliance voor 
follow-up. 
De mogelijke voordelen van een hysterecomie op de behandelduur en toxiciteit van 
behandeling voor patiënten met GTN worden besproken in hoofdstuk 5. Hoewel 
chemotherapie in het algemeen de eerste behandelkeuze is bij patiënten met GTN, 
kan hysterectomie nog steeds overwogen worden in specifieke gevallen. Alle patiën-
ten die tussen 1977 en 2012 gediagnosticeerd werden met GTN en behandeld met 
hysterectomie, werden geselecteerd uit de Nederlandse Centrale Molaregistratie en 
het archief van de Nederlandse Tumorwerkgroep voor Trofoblastziekten. In totaal 
ondergingen 109 GTN patiënten (16.5% van alle geregistreerde patiënten met GTN) 
een hysterectomie als onderdeel van hun behandeling. Het merendeel van deze 
patiënten was geclassificeerd als laag-risico (74.3%), post-mola GTN (73.5%) met 
ziekte beperkt tot de uterus (65.1%). Na hysterectomie alleen werd in 66.2% van 
de patiënten met gelokaliseerde ziekte en in 15.8% van de patiënten met gemeta-
staseerde ziekte complete remissie bereikt. Bij patiënten met gelokaliseerde ziekte, 
behandeld met hysterectomie , was sprake van een significant kortere behandelduur 
(gemiddeld respectievelijk 3.2 weken en 8.0 weken, p=0.01), met minder benodigde 
chemokuren (gemiddeld respectievelijk 1.5 en 5.8 cycli, p<0.01) dan een gematchte 
controle Group. Wij concludeerden daarom dat hysterectomie in specifieke gevallen 
nog steeds beschouwd kan worden als een effectieve behandeloptie om tumor bulk 
te elimineren dan wel reduceren. Primaire hysterectomie kan overwogen worden 
bij patiënten ouder dan veertig jaar zonder kinderwens, met gelokaliseerde ziekte. 
Patiënten met chemo-resistente ziekte kunnen baat hebben bij aanvullende hyste-
rectomie, vooral wanneer de ziekte zich beperkt tot de uterus. Voor patiënten met 
gemetastaseerde ziekte ligt het voordeel van een hysterectomie met name in het 
verwijderen van chemo-resistente tumorbulk ter bevordering van de overleving. 
Wanneer de diagnose GTN gesteld is, kunnen verschillende prognostische classifica-
tiesystemen gebruikt worden om patiënten met GTN te stratificeren voor mono- of 
polychemotherapie. Wanneer men behandelstrategieën tussen verschillende inter-
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national centra wil vergelijken, is het echter essentieel om consensus te bereiken over 
het te gebruiken classificatiesysteem en het daarbij behorende behandelprotocol. 
hoofdstuk 6 beschrijft een vergelijking tussen het Nederlandse classificatie system en 
het international gebruikte FIGO 2000 classificatiesysteem voor patiënten met GTN. 
Alle patiënten, gediagnosticeerd tussen 2003 en 2012 in het Trophoblastic Center 
in London, aanvankelijk geclassificeerd volgens FIGO 2000, werden in retrospect 
geclassificeerd volgens het Nederlandse classificatiesysteem. Ondanks de verschillen 
in gebruikte items en methode van scoren, werd in 93.4% van de patiënten een over-
eenkomstige risicoclassificatie gezien. Hoewel het Nederlandse systeem eenvoudiger 
is in gebruik, wordt in beide systemen een mate van overbehandeling verondersteld. 
Gezien de grote mate van overlap tussen de risicofactoren van het FIGO 2000 clas-
sificatie systeem, concludeerden wij dat verdere verfijning van FIGO 2000, middels 
hernieuwde univariate en multivariable analyse van de prognostische FIGO criteria 
zinvol zou zijn. 
In hoofdstuk 7 werd een re-evaluatie van alle FIGO criteria verricht om de even-
tuele mogelijkheid tot vereenvoudiging van het FIGO 2000 classificatiesysteem te 
beoordelen. Achthonderddertien GTN patiënten, gediagnosticeerd tussen 2003 en 
2012 in het Trophoblastic Center in London en gescored volgens FIGO 2000 werden 
geïdentificeerd. Met behulp van multivariable analyse en stepwise logistische regres-
sie analyse werd vervolgens beoordeeld of vereenvoudiging van FIGO 2000 mogelijk 
was. Van de acht FIGO factoren werden alleen een serum hCG voor behandeling van 
meer dan 10,000 IU/l (OR = 5.0; CI 2.5-10.4) en 100,000 IU/l (OR = 14.3; CI 4.7-44.1), 
interval groter dan 7 maanden na antecedente zwangerschap, (OR = 4.1; CI 1.0-16.2) 
en een tumor groter dan 5 cm (OR =  2.2; CI 1.3-3.6) geïdentificeerd als onafhankelijke 
voorspellers voor het ontwikkelen van resistentie voor mono-chemotherapie. Met be-
hulp van stepwise logistische regressie werd een vereenvoudigd classificatie systeem 
ontwikkeld, gebaseerd op leeftijd, serum hCG voor behandeling, aantal metastasen, 
antecedente zwangerschap en interval, maar zonder tumor grootte, eerder gefaalde 
chemotherapie en lokalisatie van metastasen. Met dit model werd slechts 1 van de 
in totaal 725 patiënten anders geclassificeerd dan volgens FIGO 2000. Hoewel het 
vereenvoudigde alternatief voor FIGO slechts gebruik maakt van vijf FIGO criteria, 
blijkt dit systeem op accurate wijze onderscheid te kunnen maken tussen patiënten 
die mono- dan wel polychemotherapy nodig hebben. 
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hoofdstuk 8 vat de belangrijkste bevindingen van dit proefschrift samen en bedis-
cussieerd deze bevindingen in bredere zin. Dit hoofdstuk richt zich daarbij vooral op 
het belang van consensus in terminologie, diagnose en behandeling. Juist bij een 
zeldzame aandoening als GTN, waarbij multi-center onderzoek en internationale 
samenwerking de enige mogelijkheid bieden om tot voldoende aantallen te komen, 
is het van groot belang om variaties in definitie, diagnose en ook behandelkeuzes 
zoveel mogelijk te beperken. Om vergelijking van Nederlandse behandelresultaten 
met andere landen mogelijk te maken, adviseren wij daarom vervanging van het Ne-
derlandse risico classificatie system voor GTN door het FIGO 2000 classificatie system. 
Gezien de mogelijkheden tot vereenvoudiging en verbetering van dit FIGO systeem, 
zou deze vervanging bij voorkeur een verder verfijnde versie omvatten. Overwegingen 
om tot een verbeterde FIGO te komen worden tot slot besproken met suggesties voor 
toekomstig onderzoek. 
A
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laatste jaren! Michelle, van Australië tot Afrika, met jou heb ik bijna alle ‘hoeken’ van 
de wereld gezien. Een kapotte auto duwen in het midden van een wildpark, maar ook 
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verplicht water drinken per order dokter Michelle als de Dengue heeft toegeslagen. 
Lieve Michelle, zullen we over een paar jaar maar eens voor de reüniereis met koters 
gaan? Lieve Mieke, want ben je toch een heerlijk nuchtere chick. Maar ondertussen 
schuiven de bedjes netjes tegen elkaar als er kleine beestjes op de loer kunnen lig-
gen.. ‘gezellig hè, ik heb jouw klamboe even over ons bed gehangen’. OpieJopie, jouw 
Afrika-liefde was allang op me overgeslagen. Maar bij jullie kunnen we ook altijd ter-
echt voor een biertje (al moest ik de 0% zelf meenemen), of een knuffel voor Thomas. 
Betere buurtjes kunnen we ons denk ik niet wensen! Lieve loekie, wie is er nou net zo 
gek als ik om tijdens een reis te gaan sporten in de woestijn, op het strand of rond te 
springen door de hotelkamer. Stuiterbal, wanneer gaan we weer?
Lieve Iris, Anne en Josanne, lieve geneeskundecrew van het eerste uur, al zien we 
elkaar soms maanden of zelfs een jaar niet, we pakken gewoon de draad weer op. 
Dat zit wel goed! Lieve schone familie, Tiny en Hennie onze kleine kletskous voelt zich 
altijd enorm op zijn gemak bij jullie (dat geklets heeft hij natuurlijk niet van mij hoor). 
Dank, voor al jullie goede zorgen en liefde voor ons en ook de kleine man. De deur 
staat altijd open voor een bordje eten, een babyfoon of gewoon een goed glas wijn. 
Robin en Rikkie die Thailand-date halen we nog in!
En dan natuurlijk mijn lieve paranimfen, hoe de organisatie van een assistentenweek-
end zo uit de hand heeft kunnen lopen! Lieve Thijsie, wat moet ik altijd lachen om 
jouw directheid. Al heb ik nog wat extra respect voor Karin als je na wat biertjes 
je grenzen altijd nét weer even weet te verleggen. Lieve Lien, Pien, Mien (hoeveel 
bijnamen heb je eigenlijk?), al bijna 6 jaar collega’s, van Rijnstate tot onderzoekstuin 
en terug! Ik waardeer jouw nuchterheid, je droge humor en natuurlijk je goede smaak 
voor bier! Lieve paranimfen, zelfs met een karmeliet in de ene hand konden jullie 
samen prima Thomas voeden met de andere, jullie zijn een fantastisch team!
En dan niet te vergeten natuurlijk ons fijne en inmiddels ook flink uitgebreide gezin! 
Bij ons in huis moet je toch echt wel je mannetje staan anders wordt er niet alleen 
niet naar je geluisterd, maar krijg je ook geen eten! (Jan en Mark jullie hebben daar 
inmiddels ook je draai wel in gevonden!). Lieve zusjes, Lieve Ragnhil en Steaffanne, 
we zijn heel verschillend, maar toch ook weer zo hetzelfde. Wat zijn jullie ontzettend 
gezellig, maar vooral ook lief! Thomas heeft het in zijn bedje soms nog over jullie! Lief 
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broertje van 1 meter 90, lieve Friedie, dank voor jullie hulp bij het zorgvuldig door-
lezen van het hele manuscript. Wanneer gaan we weer eens bubbelen met cocktails?
Lieve mams, wat laat je jezelf en ons soms toch weer schrikken, maar sterk als je bent, 
klim je er altijd weer bovenop. Het voelde, maar was natuurlijk ook ver, heel ver weg 
toen ik in Australië de berichten van thuis ontving. Er zijn er maar weinig die zo vaak 
een ziekenhuisbed hebben aangetikt en toch zo vrolijk en positief in het leven staan. 
Ik ben blij dat je weer zo snel de oude bent, we kunnen je nog lang niet missen. Lieve 
paps, van grasmaaien naar schilderen, van koken naar beton storten en dat allemaal 
binnen een dag (of allemaal de helft). Wat heb jij nog een energie. Ik waardeer je 
interesse, je oog voor detail en ook de van jou geërfde liefde voor speciaalbier. Een 
oprecht trotse papa en opa, dank je wel! En tot slot natuurlijk ook Kiyon, Thyrza, Tayte 
en Stian, achtbanen, dierentuinen, trampolines, zwembaden niks is ons te gek. Jullie 
zijn stuk voor stuk toppers! 
Lieve Opa, wat is het bijzonder dat u dit hele traject nog heeft mogen meemaken. En 
wat had oma het ook mooi gevonden om dit nog te zien. Als accountant kende u mijn 
progressie en cijferlijsten altijd al beter dan ikzelf! 
Lieve Jeremy, al had je soms echt geen idee wat dat promoveren nou allemaal inhield, 
of wat die klinische verhalen nou allemaal betekende, je hoorde mijn verhalen en 
frustraties altijd aan en kwam met de mooiste no-nonsense oplossingen. We hebben 
een drukke tijd achter de rug met afronden promotie, start nieuwe baan en daarnaast 
een klein mannetje met sterke wil, maar papa regelt dat allemaal wel.  Liefde is ook 
elkaar alles gunnen en dat doe jij als geen ander. Zonder jouw ongezouten mening is 
het leven ook maar saai!
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